https://www.camurus.com/2026-03-31https://www.camurus.com/privacy-notice/2026-03-23https://www.camurus.com/about-us/2026-01-08https://www.camurus.com/about-us/our-commitment/2025-09-05https://www.camurus.com/about-us/business-model/2025-08-22https://www.camurus.com/about-us/board-of-directors/2025-06-10https://www.camurus.com/about-us/board-of-directors/per-olof-wallstrom/2025-05-23https://www.camurus.com/about-us/board-of-directors/fredrik-tiberg/2026-03-09https://www.camurus.com/about-us/board-of-directors/hege-hellstrom/2026-02-19https://www.camurus.com/about-us/board-of-directors/jakob-lindberg/2025-05-23https://www.camurus.com/about-us/board-of-directors/stefan-persson/2025-05-23https://www.camurus.com/about-us/board-of-directors/erika-soderberg-johnsson/2025-05-23https://www.camurus.com/about-us/board-of-directors/robert-mcquade/2025-11-06https://www.camurus.com/about-us/board-of-directors/elisabeth-bjork/2026-02-19https://www.camurus.com/about-us/management-team/2024-01-04https://www.camurus.com/about-us/management-team/fredrik-tiberg/2026-03-05https://www.camurus.com/about-us/management-team/anders-vadsholt/2026-02-26https://www.camurus.com/about-us/management-team/jane-buus-laursen/2026-03-24https://www.camurus.com/about-us/management-team/richard-jameson/2025-07-01https://www.camurus.com/about-us/management-team/agneta-svedberg/2025-09-25https://www.camurus.com/about-us/management-team/annette-mattsson/2025-07-01https://www.camurus.com/about-us/management-team/fredrik-joabsson/2025-08-20https://www.camurus.com/about-us/management-team/maria-lundqvist/2025-09-25https://www.camurus.com/about-us/management-team/alberto-m-pedroncelli/2025-06-27https://www.camurus.com/about-us/management-team/susanne-lagerlund/2026-03-31https://www.camurus.com/about-us/management-team/markus-johnsson/2025-09-25https://www.camurus.com/about-us/management-team/behshad-sheldon/2025-07-01https://www.camurus.com/about-us/management-team/bo-a-c-tarras-wahlberg/2025-07-01https://www.camurus.com/about-us/code-of-conduct/2025-09-01https://www.camurus.com/about-us/vendor-code-of-conduct/2024-09-11https://www.camurus.com/science/2025-12-12https://www.camurus.com/science/products/2025-11-03https://www.camurus.com/science/rd-pipeline/2025-08-13https://www.camurus.com/science/technology/2025-08-27https://www.camurus.com/science/medical-hub/2025-12-12https://www.camurus.com/disease-areas/2026-01-21https://www.camurus.com/disease-areas/opioid-dependence/2025-12-12https://www.camurus.com/disease-areas/acromegaly/2025-12-12https://www.camurus.com/disease-areas/neuroendocrine-tumors/2025-08-13https://www.camurus.com/disease-areas/polycystic-liver-disease/2025-08-13https://www.camurus.com/disease-areas/stories/melissas-story/2026-03-09https://www.camurus.com/disease-areas/stories/wills-story/2026-03-09https://www.camurus.com/disease-areas/stories/johns-story/2026-03-09https://www.camurus.com/disease-areas/stories/lauras-story/2026-03-09https://www.camurus.com/disease-areas/stories/antonios-story/2026-03-09https://www.camurus.com/disease-areas/stories/kens-story/2026-03-09https://www.camurus.com/disease-areas/stories/daniels-story/2026-03-09https://www.camurus.com/disease-areas/stories/crys-story/2026-03-09https://www.camurus.com/disease-areas/stories/angelikis-story/2026-03-09https://www.camurus.com/disease-areas/stories/joshs-story/2026-03-09https://www.camurus.com/disease-areas/stories/kaths-story/2026-03-09https://www.camurus.com/disease-areas/stories/richards-story/2026-03-09https://www.camurus.com/disease-areas/stories/maries-and-ryans-story/2026-03-09https://www.camurus.com/disease-areas/stories/darros-story/2026-03-09https://www.camurus.com/disease-areas/stories/mattias-story/2026-03-09https://www.camurus.com/disease-areas/stories/cullan-story/2025-11-24https://www.camurus.com/sustainability/2025-12-15https://www.camurus.com/sustainability/transparency-reporting/2026-03-18https://www.camurus.com/sustainability/patients/2025-07-07https://www.camurus.com/sustainability/patients/access-to-medicines/2025-05-08https://www.camurus.com/sustainability/patients/clinical-trials/2024-10-01https://www.camurus.com/sustainability/people/2026-02-27https://www.camurus.com/sustainability/planet/2025-11-19https://www.camurus.com/sustainability/planet/plan-for-climate-neutrality/2025-11-19https://www.camurus.com/sustainability/responsible-business/2025-08-13https://www.camurus.com/sustainability/governing-documents/2026-03-26https://www.camurus.com/sustainability/sdg-analysis/2026-01-28https://www.camurus.com/sustainability/ratings/2025-12-15https://www.camurus.com/sustainability/sustainability-goals/2026-02-27https://www.camurus.com/terms-of-use/2024-08-22https://www.camurus.com/cookie-policy/2026-03-18https://www.camurus.com/investors/2026-03-17https://www.camurus.com/investors/the-share/2026-03-05https://www.camurus.com/investors/calendar/2026-01-26https://www.camurus.com/investors/presentations/2026-03-06https://www.camurus.com/investors/financial-reports/2019-10-04https://www.camurus.com/investors/financial-reports/camurus-interim-report-third-quarter-2024/2024-11-07https://www.camurus.com/investors/financial-reports/camurus-interim-report-january-march-2021/2021-05-06https://www.camurus.com/investors/financial-reports/full-year-report-2018/2019-02-06https://www.camurus.com/investors/financial-reports/camurus-interim-report-january-march-2020/2020-05-07https://www.camurus.com/investors/financial-reports/camurus-annual-report-for-2018/2019-04-15https://www.camurus.com/investors/financial-reports/full-year-report-january-december-2015/2016-02-17https://www.camurus.com/investors/financial-reports/camurus-interim-report-second-quarter-2024/2024-07-16https://www.camurus.com/investors/financial-reports/camurus-annual-report-for-2019/2020-04-08https://www.camurus.com/investors/financial-reports/camurus-interim-report-third-quarter-2020/2020-11-05https://www.camurus.com/investors/financial-reports/camurus-interim-report-january-march-2024/2024-05-13https://www.camurus.com/investors/financial-reports/camurus-annual-report-for-2023/2024-12-09https://www.camurus.com/investors/financial-reports/camurus-full-year-report-2024/2025-02-13https://www.camurus.com/investors/financial-reports/interim-report-january-june-2017/2017-07-13https://www.camurus.com/investors/financial-reports/interim-report-january-march-2017/2017-05-03https://www.camurus.com/investors/financial-reports/camurus-interim-report-january-march-2025/2025-05-15https://www.camurus.com/investors/financial-reports/full-year-report-2017/2018-02-15https://www.camurus.com/investors/financial-reports/camurus-full-year-report-2023/2024-02-15https://www.camurus.com/investors/financial-reports/interim-report-january-september-2017/2017-10-26https://www.camurus.com/investors/financial-reports/camurus-interim-report-second-quarter-2021/2021-07-15https://www.camurus.com/investors/financial-reports/camurus-ab-interim-report-january---september-2015/2015-10-22https://www.camurus.com/investors/financial-reports/interim-report-january-june-2019/2019-07-18https://www.camurus.com/investors/financial-reports/camurus-annual-report-for-2015-released/2016-03-30https://www.camurus.com/investors/financial-reports/camurus-full-year-report-2021/2024-12-09https://www.camurus.com/investors/financial-reports/interim-report-january-june-2016/2016-07-14https://www.camurus.com/investors/financial-reports/camurus-annual-report-for-2022/2024-12-09https://www.camurus.com/investors/financial-reports/camurus-full-year-report-2019/2020-02-12https://www.camurus.com/investors/financial-reports/full-year-report-2016/2017-02-16https://www.camurus.com/investors/financial-reports/camurus-full-year-report-2022/2023-02-14https://www.camurus.com/investors/financial-reports/interim-report-january-september-2016/2016-11-08https://www.camurus.com/investors/financial-reports/camurus-interim-report-third-quarter-2022/2022-11-10https://www.camurus.com/investors/financial-reports/interim-report-january-september-2018/2018-10-25https://www.camurus.com/investors/financial-reports/camurus-annual-report-for-2021/2024-12-09https://www.camurus.com/investors/financial-reports/camurus-interim-report-january-march-2022/2022-05-12https://www.camurus.com/investors/financial-reports/camurus-interim-report-second-quarter-2022/2022-07-15https://www.camurus.com/investors/financial-reports/camurus-annual-report-for-2017/2018-03-22https://www.camurus.com/investors/financial-reports/camurus-annual-report-for-2016-released/2017-03-30https://www.camurus.com/investors/financial-reports/camurus-interim-report-second-quarter-2020/2020-07-16https://www.camurus.com/investors/financial-reports/interim-report-january-march-2018/2018-05-03https://www.camurus.com/investors/financial-reports/camurus-interim-report-third-quarter-2023/2023-11-09https://www.camurus.com/investors/financial-reports/camurus-annual-report-for-2020/2021-04-14https://www.camurus.com/investors/financial-reports/camurus-interim-report-january-september-2019/2019-11-08https://www.camurus.com/investors/financial-reports/camurus-interim-report-second-quarter-2023/2023-07-18https://www.camurus.com/investors/financial-reports/camurus-full-year-report-2020/2021-02-11https://www.camurus.com/investors/financial-reports/interim-report-january-june-2018/2018-07-17https://www.camurus.com/investors/financial-reports/camurus-interim-report-third-quarter-2021/2021-11-04https://www.camurus.com/investors/financial-reports/camurus-interim-report-january-march-2019/2019-05-09https://www.camurus.com/investors/financial-reports/camurus-interim-report-january-march-2016/2016-05-17https://www.camurus.com/investors/financial-reports/camurus-interim-report-january-march-2023/2023-05-10https://www.camurus.com/investors/financial-reports/camurus-interim-report-second-quarter-2025/2025-07-17https://www.camurus.com/investors/financial-reports/camurus-annual-report-for-2024/2025-12-04https://www.camurus.com/investors/financial-reports/camurus-full-year-report-2025/2026-02-12https://www.camurus.com/investors/financial-reports/camurus-interim-report-third-quarter-2025/2025-11-06https://www.camurus.com/investors/analysts/2026-02-12https://www.camurus.com/investors/corporate-governance/2025-04-30https://www.camurus.com/investors/corporate-governance/committees/2024-05-16https://www.camurus.com/investors/corporate-governance/remuneration/2026-01-26https://www.camurus.com/investors/corporate-governance/general-meetings/2021-10-28https://www.camurus.com/investors/corporate-governance/auditors/2024-05-16https://www.camurus.com/investors/corporate-governance/incentive-programs/2025-07-17https://www.camurus.com/investors/corporate-governance/articles-of-association/2024-05-16https://www.camurus.com/investors/corporate-governance/nomination-committee/2024-12-11https://www.camurus.com/investors/corporate-governance/agm/2026-01-26https://www.camurus.com/investors/ceo-message/2026-02-12https://www.camurus.com/investors/investor-contact/2025-08-13https://www.camurus.com/investors/subscription/2023-07-07https://www.camurus.com/partnering/2025-08-20https://www.camurus.com/media/2024-09-18https://www.camurus.com/media/press-releases/2019-10-02https://www.camurus.com/media/press-releases/2026/change-in-number-of-shares-and-votes-in-camurus-2026-03-31/2026-03-31https://www.camurus.com/media/press-releases/2026/camurus-announces-fda-acceptance-of-nda-resubmission-for-oclaiz-for-the-treatment-of-acromegaly/2026-01-09https://www.camurus.com/media/press-releases/2026/camurus-full-year-report-2025/2026-02-12https://www.camurus.com/media/press-releases/2026/change-in-number-of-shares-and-votes-in-camurus/2026-02-27https://www.camurus.com/media/press-releases/2026/camurus-appoints-jane-buus-laursen-as-chief-corporate-development-officer/2026-02-17https://www.camurus.com/media/press-releases/2025/resolutions-at-the-annual-general-meeting-2025-in-camurus/2025-05-27https://www.camurus.com/media/press-releases/2025/camurus-to-present-at-jefferies-global-healthcare-conference/2025-05-22https://www.camurus.com/media/press-releases/2025/camurus-interim-report-january-march-2025/2025-05-15https://www.camurus.com/media/press-releases/2025/camurus-appoints-anders-vadsholt-as-chief-financial-officer/2025-05-14https://www.camurus.com/media/press-releases/2025/camurus-launches-buvidal-weekly-and-monthly-in-portugal/2025-05-08https://www.camurus.com/media/press-releases/2025/chmp-recommends-approval-of-oczyesa-for-treatment-of-acromegaly-in-the-eu/2025-04-25https://www.camurus.com/media/press-releases/2025/camurus-ceo-fredrik-tiberg-receives-the-arthur-d-little-nordic-life-science-award/2025-03-19https://www.camurus.com/media/press-releases/2025/camurus-receives-ethifinance-esg-platinum-medal/2025-03-14https://www.camurus.com/media/press-releases/2025/jon-garay-alonso-will-leave-position-as-camurus-cfo/2025-03-03https://www.camurus.com/media/press-releases/2025/camurus-full-year-report-2024/2025-02-13https://www.camurus.com/media/press-releases/2025/camurus-fourth-quarter-and-full-year-2024-earnings-above-previous-estimates/2025-01-23https://www.camurus.com/media/press-releases/2025/buvidal-weekly-and-monthly-now-available-to-patients-in-switzerland/2025-01-17https://www.camurus.com/media/press-releases/2025/change-in-number-of-shares-and-votes-in-camurus/2025-06-30https://www.camurus.com/media/press-releases/2025/camurus-announces-approval-of-oczyesa-for-the-treatment-of-acromegaly-in-the-uk/2025-08-28https://www.camurus.com/media/press-releases/2025/camurus-achieves-esg-risk-rating-low-by-sustainalytics/2025-08-20https://www.camurus.com/media/press-releases/2025/camurus-ceo-sells-shares/2025-07-24https://www.camurus.com/media/press-releases/2025/camurus-interim-report-second-quarter-2025/2025-07-17https://www.camurus.com/media/press-releases/2025/camurus-oczyesa-receives-marketing-authorization-for-treatment-of-acromegaly-in-the-eu/2025-07-01https://www.camurus.com/media/press-releases/2025/camurus-positano-study-shows-treatment-effects-with-cam2029-in-polycystic-liver-disease-patients/2025-06-18https://www.camurus.com/media/press-releases/2025/exercise-in-camurus-employee-stock-options-program-20222026/2025-06-11https://www.camurus.com/media/press-releases/2025/camurus-and-lilly-enter-collaboration-and-license-agreement-for-long-acting-fluidcrystal-incretins/2025-06-03https://www.camurus.com/media/press-releases/2025/camurus-board-of-directors-exercises-authorization-for-repurchase-of-shares-for-the-purpose-of-securing-the-companys-commitments-under-the-performance-share-plan-20252028/2025-05-27https://www.camurus.com/media/press-releases/2025/change-in-number-of-shares-and-votes-in-camurus-2025-09-30/2025-09-30https://www.camurus.com/media/press-releases/2025/camurus-launches-long-acting-oczyesa-for-the-treatment-of-acromegaly/2025-11-03https://www.camurus.com/media/press-releases/2025/camurus-receives-highest-level-in-my-green-lab-certification/2025-11-04https://www.camurus.com/media/press-releases/2025/camurus-submits-its-first-cdp-disclosure/2025-09-19https://www.camurus.com/media/press-releases/2025/exercise-in-camurus-employee-stock-options-program-20222026-2025-09-15/2025-09-15https://www.camurus.com/media/press-releases/2025/camurus-nomination-committee-appointed-for-the-annual-general-meeting-2026/2025-11-13https://www.camurus.com/media/press-releases/2025/camurus-reports-positive-topline-results-for-cam2056-semaglutide-monthly-depot/2025-11-10https://www.camurus.com/media/press-releases/2025/camurus-to-present-at-jefferies-london-healthcare-conference/2025-11-12https://www.camurus.com/media/press-releases/2025/change-in-number-of-shares-and-votes-in-camurus-2025-11-28/2025-11-28https://www.camurus.com/media/press-releases/2025/camurus-annual-report-for-2024/2025-04-30https://www.camurus.com/media/press-releases/2025/camurus-interim-report-third-quarter-2025/2025-11-06https://www.camurus.com/media/press-releases/2025/change-in-number-of-shares-and-votes-in-camurus-2025-12-30/2025-12-30https://www.camurus.com/media/press-releases/2025/camurus-and-gubra-enter-into-a-collaboration-and-license-agreement-to-develop-a-long-acting-treatment-for-hypoparathyroidism/2025-12-16https://www.camurus.com/media/press-releases/2025/notice-of-annual-general-meeting-2025-in-camurus-ab-publ-2025/2025-04-23https://www.camurus.com/media/press-releases/2024/change-in-number-of-shares-and-votes-in-camurus/2024-06-28https://www.camurus.com/media/press-releases/2024/completed-enrollment-in-the-positano-study-of-cam2029-in-patients-with-polycystic-liver-disease/2024-02-08https://www.camurus.com/media/press-releases/2024/camurus-appoints-behshad-sheldon-as-president-of-camurus-inc-/2024-02-13https://www.camurus.com/media/press-releases/2024/camurus-full-year-report-2023/2024-02-15https://www.camurus.com/media/press-releases/2024/camurus-announces-fda-acceptance-of-nda-submission-for-oclaiz-for-treatment-of-acromegaly/2024-03-05https://www.camurus.com/media/press-releases/2024/camurus-annual-report-for-2023/2024-03-28https://www.camurus.com/media/press-releases/2024/notice-of-annual-general-meeting-2024-in-camurus-publ/2024-04-02https://www.camurus.com/media/press-releases/2024/camurus-interim-report-january-march-2024/2024-05-08https://www.camurus.com/media/press-releases/2024/exercise-in-camurus-employee-stock-options-program-20212024/2024-09-19https://www.camurus.com/media/press-releases/2024/ema-positive-opinion-for-orphan-drug-designation-to-camurus-octreotide-sc-depot-for-the-treatment-of-polycystic-liver-disease/2024-09-20https://www.camurus.com/media/press-releases/2024/change-in-number-of-shares-and-votes-in-camurus-2024-09-30/2025-06-26https://www.camurus.com/media/press-releases/2024/camurus-provides-regulatory-update-on-the-us-nda-for-cam2029-in-acromegaly/2024-10-21https://www.camurus.com/media/press-releases/2024/camurus-improves-esg-rating-score-by-msci/2024-10-28https://www.camurus.com/media/press-releases/2024/camurus-interim-report-third-quarter-2024/2024-11-07https://www.camurus.com/media/press-releases/2024/camurus-to-present-at-jefferies-london-healthcare-conference/2024-11-11https://www.camurus.com/media/press-releases/2024/camurus-nomination-committee-appointed-for-the-annual-general-meeting-2025/2024-11-12https://www.camurus.com/media/press-releases/2024/resolutions-at-the-annual-general-meeting-2024-in-camurus/2024-05-08https://www.camurus.com/media/press-releases/2024/camurus-receives-ema-acceptance-of-maa-filing-for-octreotide-sc-depot-cam2029-for-the-treatment-of-acromegaly/2024-05-23https://www.camurus.com/media/press-releases/2024/camurus-to-present-at-jefferies-2024-healthcare-conference-new-york/2024-05-28https://www.camurus.com/media/press-releases/2024/camurus-board-of-directors-exercises-authorization-for-repurchase-of-shares-for-the-purpose-of-securing-the-companys-commitments-under-the-performance-share-plan-20242027/2024-05-30https://www.camurus.com/media/press-releases/2024/exercise-of-camurus-employee-stock-options-program-20212024/2024-06-12https://www.camurus.com/media/press-releases/2024/camurus-submits-its-first-un-global-compact-communication-on-progress-and-renews-the-nasdaq-transparency-partner-certificate/2024-06-24https://www.camurus.com/media/press-releases/2024/new-publication-shows-effectiveness-data-for-weekly-and-monthly-buprenorphine-injections-in-treating-opioid-dependence-in-individuals-using-fentanyl/2024-06-25https://www.camurus.com/media/press-releases/2024/camurus-announces-positive-phase-3-results-from-the-acroinnova-2-study-of-octreotide-sc-depot-cam2029-in-acromegaly-patients/2024-07-15https://www.camurus.com/media/press-releases/2024/camurus-interim-report-second-quarter-2024/2024-07-16https://www.camurus.com/media/press-releases/2024/camurus-recognized-in-fortunes-top-25-leading-the-charge-spotlighting-the-25-companies-smashing-the-glass-ceiling/2024-07-25https://www.camurus.com/media/press-releases/2024/change-in-number-of-shares-and-votes-in-camurus-2024-12-30/2024-12-30https://www.camurus.com/media/press-releases/2023/camurus-nomination-committee-appointed-for-the-annual-general-meeting-2024/2023-10-18https://www.camurus.com/media/press-releases/2023/camurus-raises-financial-guidance-for-the-full-year-2023/2023-10-23https://www.camurus.com/media/press-releases/2023/camurus-to-present-at-jefferies-2023-healthcare-conference-london/2023-11-01https://www.camurus.com/media/press-releases/2023/camurus-receives-improved-esg-risk-rating-by-sustainalytics/2023-11-06https://www.camurus.com/media/press-releases/2023/camurus-interim-report-third-quarter-2023/2023-11-09https://www.camurus.com/media/press-releases/2023/camurus-announces-completed-enrollment-in-the-phase-3-sorento-study-of-cam2029-in-patients-with-neuroendocrine-tumors/2023-12-14https://www.camurus.com/media/press-releases/2023/camurus-to-enter-large-cap-segment-on-nasdaq-stockholm/2023-12-20https://www.camurus.com/media/press-releases/2023/camurus-submits-new-drug-application-to-the-us-fda-for-oclaiz-for-treatment-of-acromegaly/2023-12-21https://www.camurus.com/media/press-releases/2023/change-in-number-of-shares-and-votes-in-camurus-2023-12-29/2023-12-29https://www.camurus.com/media/press-releases/2023/camurus-establishes-new-sustainable-headquarters-and-laboratories-in-science-village-lund/2023-09-26https://www.camurus.com/media/press-releases/2023/resolutions-at-the-annual-general-meeting-2023-in-camurus/2023-05-10https://www.camurus.com/media/press-releases/2023/camurus-announces-fda-approval-of-brixadi-for-the-treatment-of-moderate-to-severe-opioid-use-disorder/2023-05-23https://www.camurus.com/media/press-releases/2023/camurus-to-present-at-jefferies-2023-healthcare-conference-new-york/2023-05-29https://www.camurus.com/media/press-releases/2023/change-in-number-of-shares-and-votes-in-camurus/2023-05-31https://www.camurus.com/media/press-releases/2023/camurus-accepted-as-participant-of-the-united-nations-global-compact/2023-06-19https://www.camurus.com/media/press-releases/2023/camurus-octreotide-sc-depot-cam2029-achieves-superior-treatment-response-compared-to-placebo-in-phase-3-acromegaly-trial/2023-06-20https://www.camurus.com/media/press-releases/2023/camurus-announces-new-phase-3-data-reinforcing-long-term-safety-and-efficacy-of-octreotide-sc-depot-cam2029-in-patients-with-acromegaly/2023-07-17https://www.camurus.com/media/press-releases/2023/camurus-interim-report-second-quarter-2023/2023-07-18https://www.camurus.com/media/press-releases/2023/exercise-of-camurus-subscription-warrant-program-20202023/2023-08-25https://www.camurus.com/media/press-releases/2023/change-in-number-of-shares-and-votes-in-camurus-2023-08-31/2023-08-31https://www.camurus.com/media/press-releases/2023/camurus-announces-us-launch-of-brixadi-for-the-treatment-of-moderate-to-severe-opioid-use-disorder-by-braeburn/2023-09-05https://www.camurus.com/media/press-releases/2023/camurus-withdraws-variation-application-for-cam2038-to-include-chronic-pain/2023-02-13https://www.camurus.com/media/press-releases/2023/camurus-full-year-report-2022/2023-02-14https://www.camurus.com/media/press-releases/2023/camurus-annual-report-for-2022/2023-03-30https://www.camurus.com/media/press-releases/2023/notice-of-annual-general-meeting-2023-in-camurus-ab-publ/2023-04-04https://www.camurus.com/media/press-releases/2023/camurus-appoints-alberto-pedroncelli-as-chief-medical-officer/2023-04-04https://www.camurus.com/media/press-releases/2023/camurus-interim-report-january-march-2023/2023-05-10https://www.camurus.com/media/press-releases/2022/camurus-presenting-five-year-vision-for-growth-and-financial-outlook-at-capital-markets-and-rd-day/2022-09-06https://www.camurus.com/media/press-releases/2022/camurus-annual-report-for-2021/2022-04-06https://www.camurus.com/media/press-releases/2022/notice-of-annual-general-meeting-2022-in-camurus-ab-publ/2022-04-06https://www.camurus.com/media/press-releases/2022/2021-and-2020-lipid-science-prize-awarded-to-inventors-of-m-rna-and-lipid-nanoparticle-technologies/2022-04-04https://www.camurus.com/media/press-releases/2022/camurus-supports-international-overdose-awareness-day-2022/2022-08-30https://www.camurus.com/media/press-releases/2022/change-in-number-of-shares-and-votes-in-camurus-2022-08-31/2022-08-31https://www.camurus.com/media/press-releases/2022/update-of-change-in-number-of-shares-and-votes-in-camurus/2022-08-31https://www.camurus.com/media/press-releases/2022/camurus-nomination-committee-appointed-for-the-annual-general-meeting-2023/2022-10-19https://www.camurus.com/media/press-releases/2022/camurus-supports-two-global-awareness-days-for-rare-diseases/2022-10-28https://www.camurus.com/media/press-releases/2022/camurus-to-present-at-jefferies-2022-healthcare-conference-london/2022-11-11https://www.camurus.com/media/press-releases/2022/camurus-announces-that-braeburn-resubmits-nda-for-brixadi-in-the-us/2022-11-23https://www.camurus.com/media/press-releases/2022/camurus-announces-pdufa-date-for-brixadi-nda-for-the-treatment-of-opioid-use-disorder-in-the-us/2022-12-08https://www.camurus.com/media/press-releases/2022/invitation-to-camurus-capital-markets-and-rd-day-6-september-2022/2022-06-10https://www.camurus.com/media/press-releases/2022/camurus-interim-report-second-quarter-2022/2022-07-15https://www.camurus.com/media/press-releases/2022/solasia-acquires-episil-oral-liquid-business-from-camurus/2022-07-08https://www.camurus.com/media/press-releases/2022/change-in-number-of-shares-and-votes-in-camurus-2022-06-30/2022-06-30https://www.camurus.com/media/press-releases/2022/camurus-appoints-jonas-duborn-as-head-of-compliance/2022-06-14https://www.camurus.com/media/press-releases/2022/exercise-of-camurus-subscription-warrant-program-20192022/2022-08-23https://www.camurus.com/media/press-releases/2022/change-in-number-of-shares-and-votes-in-camurus-2022-12-30/2022-12-30https://www.camurus.com/media/press-releases/2022/camurus-to-present-at-jefferies-2022-healthcare-conference-new-york/2022-06-07https://www.camurus.com/media/press-releases/2022/change-in-number-of-shares-and-votes-in-camurus/2022-05-31https://www.camurus.com/media/press-releases/2022/program-for-camurus-capital-markets-and-rd-day-6-september-2022/2022-08-26https://www.camurus.com/media/press-releases/2022/resolutions-at-the-annual-general-meeting-2022-in-camurus/2022-05-12https://www.camurus.com/media/press-releases/2022/camurus-interim-report-third-quarter-2022/2022-11-10https://www.camurus.com/media/press-releases/2022/camurus-full-year-report-2021/2022-02-16https://www.camurus.com/media/press-releases/2022/camurus-interim-report-january-march-2022/2022-05-12https://www.camurus.com/media/press-releases/2022/camurus-announces-dosing-initiated-in-phase-3-trial-of-weekly-setmelanotide-in-patients-with-genetic-obesity-disorder/2022-01-13https://www.camurus.com/media/press-releases/2021/change-in-number-of-shares-and-votes-in-camurus/2021-12-30https://www.camurus.com/media/press-releases/2021/braeburn-receives-new-complete-response-letter-for-brixadi-in-the-us/2021-12-15https://www.camurus.com/media/press-releases/2021/the-european-medicines-agency-accepts-application-to-extend-the-buvidal-indication-to-include-treatment-of-chronic-pain/2021-11-30https://www.camurus.com/media/press-releases/2021/camurus-announces-dosing-initiated-in-phase-3-study-of-cam2029-in-patients-with-neuroendocrine-tumors/2021-11-11https://www.camurus.com/media/press-releases/2021/camurus-interim-report-third-quarter-2021/2021-11-04https://www.camurus.com/media/press-releases/2021/camurus-nomination-committee-appointed-for-the-annual-general-meeting-2022/2021-10-27https://www.camurus.com/media/press-releases/2021/camurus-appoints-jon-u-garay-alonso-as-chief-financial-officer/2021-10-13https://www.camurus.com/media/press-releases/2021/change-in-number-of-shares-and-votes-in-camurus-2021-09-30/2021-09-30https://www.camurus.com/media/press-releases/2021/fda-grants-orphan-drug-designation-in-the-us-for-cam2029-for-the-treatment-of-polycystic-liver-disease/2021-09-16https://www.camurus.com/media/press-releases/2021/camurus-chief-financial-officer-cfo-will-leave-the-company/2021-09-15https://www.camurus.com/media/press-releases/2021/change-in-number-of-shares-and-votes-in-camurus-2021-08-31/2021-08-31https://www.camurus.com/media/press-releases/2021/camurus-interim-report-second-quarter-2021/2021-07-15https://www.camurus.com/media/press-releases/2021/change-in-number-of-shares-and-votes-in-camurus-2021-06-30/2021-06-30https://www.camurus.com/media/press-releases/2021/camurus-announces-pdufa-date-for-brixadi-for-the-treatment-of-opioid-use-disorder-in-the-us/2021-06-26https://www.camurus.com/media/press-releases/2021/camurus-announces-braeburn-resubmits-new-drug-application-for-brixadi-in-the-us/2021-06-15https://www.camurus.com/media/press-releases/2021/change-in-number-of-shares-and-votes-in-camurus-2021-05-31/2021-05-31https://www.camurus.com/media/press-releases/2021/exercise-of-camurus-subscription-warrant-program-20182021/2021-05-21https://www.camurus.com/media/press-releases/2021/camurus-receives-carnegie-sustainability-award-2021/2021-05-19https://www.camurus.com/media/press-releases/2021/camurus-announces-publication-showing-superior-patient-treatment-satisfaction-with-buvidal-weekly-and-monthly-depot-injections-in-opioid-dependence/2021-05-10https://www.camurus.com/media/press-releases/2021/resolutions-at-the-annual-general-meeting-2021-in-camurus/2021-05-06https://www.camurus.com/media/press-releases/2021/camurus-interim-report-january-march-2021/2021-05-06https://www.camurus.com/media/press-releases/2021/the-australian-tga-approves-key-label-updates-to-buvidal-for-treatment-of-opioid-dependence/2021-05-03https://www.camurus.com/media/press-releases/2021/camurus-annual-report-for-2020/2021-04-14https://www.camurus.com/media/press-releases/2021/notice-of-annual-general-meeting-2021-in-camurus-ab-publ/2021-03-30https://www.camurus.com/media/press-releases/2021/camurus-receives-positive-chmp-opinion-for-buvidal-160mg-monthly-dose-for-the-treatment-of-opioid-dependence/2021-03-26https://www.camurus.com/media/press-releases/2021/camurus-full-year-report-2020/2021-02-11https://www.camurus.com/media/press-releases/2021/change-in-number-of-shares-and-votes-in-camurus-2021-01-29/2021-01-29https://www.camurus.com/media/press-releases/2021/camurus-appoints-andrew-mclean-as-vice-president-corporate-development-and-senior-counsel/2021-01-04https://www.camurus.com/media/press-releases/2020/change-in-number-of-shares-and-votes-in-camurus/2020-12-30https://www.camurus.com/media/press-releases/2020/swissmedic-approves-buvidal-for-the-treatment-of-opioid-dependence/2020-12-18https://www.camurus.com/media/press-releases/2020/exercise-of-camurus-subscription-warrant-program-20172020/2020-12-18https://www.camurus.com/media/press-releases/2020/camurus-announces-outcome-of-the-arbitration-process-with-braeburn/2020-12-10https://www.camurus.com/media/press-releases/2020/camurus-announces-that-braeburn-receives-complete-response-letter-for-brixadi-for-opioid-use-disorder-in-the-us/2020-12-02https://www.camurus.com/media/press-releases/2020/change-in-number-of-shares-and-votes-in-camurus-2020-11-30/2020-11-30https://www.camurus.com/media/press-releases/2020/camurus-interim-report-third-quarter-2020/2020-11-05https://www.camurus.com/media/press-releases/2020/camurus-nomination-committee-appointed-for-the-annual-general-meeting-2021/2020-10-23https://www.camurus.com/media/press-releases/2020/change-in-number-of-shares-and-votes-in-camurus-2020-07-31/2020-07-31https://www.camurus.com/media/press-releases/2020/camurus-interim-report-second-quarter-2020/2020-07-16https://www.camurus.com/media/press-releases/2020/camurus-has-completed-a-directed-share-issue-of-2-million-shares-raising-proceeds-of-sek-300-million/2020-07-02https://www.camurus.com/media/press-releases/2020/camurus-intends-to-carry-out-a-directed-share-issue-of-approximately-sek-300-million/2020-07-01https://www.camurus.com/media/press-releases/2020/positive-results-from-phase-2-study-of-once-weekly-fluidcrystal-formulation-of-setmelanotide-in-healthy-volunteers-with-obesity/2020-06-24https://www.camurus.com/media/press-releases/2020/camurus-raises-full-year-2020-revenue-guidance/2020-06-23https://www.camurus.com/media/press-releases/2020/braeburn-and-camurus-enter-arbitration-proceedings-in-england/2020-06-15https://www.camurus.com/media/press-releases/2020/camurus-announces-submission-of-request-for-final-approval-of-brixadi-for-the-treatment-of-opioid-use-disorder-in-the-us/2020-06-01https://www.camurus.com/media/press-releases/2020/camurus-buvidal-reimbursed-in-sweden-for-the-treatment-of-opioid-dependence/2020-05-14https://www.camurus.com/media/press-releases/2020/resolutions-at-the-annual-general-meeting-2020-in-camurus/2020-05-07https://www.camurus.com/media/press-releases/2020/camurus-interim-report-january-march-2020/2020-05-07https://www.camurus.com/media/press-releases/2020/camurus-annual-report-for-2019/2020-04-08https://www.camurus.com/media/press-releases/2020/notice-of-annual-general-meeting-2020-in-camurus-ab-publ/2020-04-06https://www.camurus.com/media/press-releases/2020/camurus-announces-strong-first-quarter-demand-for-buvidal/2020-04-02https://www.camurus.com/media/press-releases/2020/camurus-full-year-report-2019/2020-02-12https://www.camurus.com/media/press-releases/2019/change-in-number-of-shares-and-votes-in-camurus/2019-12-30https://www.camurus.com/media/press-releases/2019/camurus-has-completed-a-directed-share-issue-of-approximately-37-million-shares-raising-proceeds-of-approximately-300-msek/2019-12-06https://www.camurus.com/media/press-releases/2019/camurus-intends-to-launch-a-directed-share-issue-of-up-to-300-msek/2019-12-05https://www.camurus.com/media/press-releases/2019/camurus-announces-new-study-results-showing-superior-patient-reported-outcomes-with-buvidal-versus-standard-of-care-in-treatment-of-opioid-dependence/2019-11-26https://www.camurus.com/media/press-releases/2019/camurus-interim-report-january-september-2019/2019-11-08https://www.camurus.com/media/press-releases/2019/camurus-announces-that-fda-grants-braeburns-citizen-petition-eliminating-the-risk-of-further-blocking-of-brixadi-from-the-us-market/2019-11-08https://www.camurus.com/media/press-releases/2019/camurus-to-present-at-jefferies-2019-london-healthcare-conference/2019-10-21https://www.camurus.com/media/press-releases/2019/camurus-nomination-committee-appointed-for-the-annual-general-meeting-2020/2019-10-15https://www.camurus.com/media/press-releases/2019/australian-minister-for-health-announced-pbs-listing-of-buvidal-weekly-and-monthly-for-treatment-of-opioid-dependence/2019-08-26https://www.camurus.com/media/press-releases/2019/camurus-announces-positive-outcome-of-us-court-proceeding-about-final-approval-of-brixadi/2019-07-23https://www.camurus.com/media/press-releases/2019/interim-report-january-june-2019/2019-07-18https://www.camurus.com/media/press-releases/2019/ra-pharmaceuticals-and-camurus-announce-exclusive-license-agreement-for-fluidcrystal-extended-release-formulation-of-zilucoplan/2019-07-16https://www.camurus.com/media/press-releases/2019/camurus-receives-ind-acceptance-from-the-fda-to-enter-phase-3-with-cam2029-for-treatment-of-acromegaly/2019-06-20https://www.camurus.com/media/press-releases/2019/camurus-announces-publication-of-phase-3-study-results-showing-long-term-safety-efficacy-and-high-rates-of-patient-satisfaction-with-buvidal/2019-06-04https://www.camurus.com/media/press-releases/2019/resolutions-at-the-annual-general-meeting-2019-in-camurus/2019-05-09https://www.camurus.com/media/press-releases/2019/camurus-interim-report-january-march-2019/2019-05-09https://www.camurus.com/media/press-releases/2019/camurus-to-present-interim-report-january-march-2019-on-9-may/2019-05-07https://www.camurus.com/media/press-releases/2019/camurus-annual-report-for-2018/2019-04-15https://www.camurus.com/media/press-releases/2019/braeburn-initiates-court-proceedings-to-overturn-exclusivity-and-seeks-immediate-market-approval-of-brixadi-in-the-us/2019-04-09https://www.camurus.com/media/press-releases/2019/positive-treatment-results-for-buvidal-in-fentanyl-users-presented-at-the-asam-50th-annual-conference/2019-04-06https://www.camurus.com/media/press-releases/2019/notice-of-annual-general-meeting-2019-in-camurus-ab-publ/2019-04-05https://www.camurus.com/media/press-releases/2019/change-in-number-of-shares-and-votes-in-camurus-2019-03-29/2019-03-29https://www.camurus.com/media/press-releases/2019/camurus-rights-issue-oversubscribed/2019-03-27https://www.camurus.com/media/press-releases/2019/new-date-for-publication-of-camurus-annual-report-2018/2019-03-26https://www.camurus.com/media/press-releases/2019/camurus-publishes-prospectus-relating-to-the-rights-issue/2019-03-08https://www.camurus.com/media/press-releases/2019/resolutions-at-the-extraordinary-general-meeting-in-camurus/2019-03-05https://www.camurus.com/media/press-releases/2019/camurus-announces-the-terms-of-its-rights-issue/2019-02-28https://www.camurus.com/media/press-releases/2019/camurus-to-present-at-the-cowen-and-company-annual-healthcare-conference-2019/2019-02-14https://www.camurus.com/media/press-releases/2019/full-year-report-2018/2019-02-06https://www.camurus.com/media/press-releases/2019/notice-of-extraordinary-general-meeting-in-camurus-ab-publ/2019-02-06https://www.camurus.com/media/press-releases/2019/camurus-to-progress-commercialization-of-buvidal-and-advance-pipeline-programs-through-a-fully-underwritten-rights-issue-of-sek-400-million/2019-02-06https://www.camurus.com/media/press-releases/2019/camurus-to-present-full-year-2018-results-on-6-february/2019-02-01https://www.camurus.com/media/press-releases/2019/camurus-to-present-at-seb-biotech-seminar-in-stockholm/2019-01-18https://www.camurus.com/media/press-releases/2019/buvidal-launched-as-the-first-long-acting-opioid-dependence-treatment-in-the-eu/2019-01-11https://www.camurus.com/media/press-releases/2018/us-fda-issues-a-tentative-approval-of-brixadi-buprenorphine-extended-release-injection-for-treatment-of-opioid-use-disorder/2018-12-23https://www.camurus.com/media/press-releases/2018/camurus-capital-markets-and-rd-day-11-december-2018/2018-12-11https://www.camurus.com/media/press-releases/2018/buvidal-weekly-and-buvidal-monthly-cam2038-approved-in-australia-as-the-first-long-acting-treatment-of-opioid-dependence/2018-11-28https://www.camurus.com/media/press-releases/2018/program-for-camurus-capital-markets-and-rd-day-11-december-2018/2018-11-28https://www.camurus.com/media/press-releases/2018/camurus-receives-eu-approval-for-weekly-and-monthly-buvidal-cam2038-for-opioid-dependence/2018-11-22https://www.camurus.com/media/press-releases/2018/interim-report-january-september-2018/2018-10-25https://www.camurus.com/media/press-releases/2018/camurus-nomination-committee-appointed-for-the-annual-general-meeting-2019/2018-10-16https://www.camurus.com/media/press-releases/2018/camurus-to-present-at-jefferies-2018-london-healthcare-conference/2018-10-10https://www.camurus.com/media/press-releases/2018/save-the-date-camurus-capital-markets-and-rd-day-11-december-2018/2018-10-09https://www.camurus.com/media/press-releases/2018/chmp-recommends-approval-of-buvidal-cam2038-for-the-treatment-of-opioid-dependence/2018-09-21https://www.camurus.com/media/press-releases/2018/camurus-announces-positive-topline-phase-3-results-for-cam2038-in-opioid-experienced-patients-with-chronic-low-back-pain/2018-09-18https://www.camurus.com/media/press-releases/2018/interim-report-january-june-2018/2018-07-17https://www.camurus.com/media/press-releases/2018/camurus-announces-pdufa-date-for-cam2038-for-the-treatment-of-opioid-use-disorder/2018-07-16https://www.camurus.com/media/press-releases/2018/change-in-the-number-of-shares-and-votes-in-camurus-ab/2018-06-29https://www.camurus.com/media/press-releases/2018/camurus-has-completed-a-directed-share-issue-of-11-million-shares-raising-proceeds-of-approximately-sek-102-million/2018-06-29https://www.camurus.com/media/press-releases/2018/camurus-updates-its-investor-relations-website/2018-06-28https://www.camurus.com/media/press-releases/2018/camurus-intends-to-launch-a-directed-share-issue-of-approx-msek-100/2018-06-28https://www.camurus.com/media/press-releases/2018/camurus-and-medison-enter-into-commercialization-agreement-for-cam2038-in-israel/2018-06-12https://www.camurus.com/media/press-releases/2018/camurus-announces-positive-topline-results-from-phase-1-study-of-long-acting-treprostinil-for-the-treatment-of-pulmonary-arterial-hypertension/2018-05-31https://www.camurus.com/media/press-releases/2018/camurus-announces-nda-resubmission-of-weekly-and-monthly-buprenorphine-depots-to-fda/2018-05-28https://www.camurus.com/media/press-releases/2018/camurus-to-present-at-the-jefferies-2018-global-healthcare-conference/2018-05-25https://www.camurus.com/media/press-releases/2018/jama-internal-medicine-publishes-positive-phase-3-pivotal-study-results-for-camurus-long-acting-buprenorphine-depots-for-opioid-use-disorder/2018-05-14https://www.camurus.com/media/press-releases/2018/resolutions-at-the-annual-general-meeting-2018-in-camurus/2018-05-03https://www.camurus.com/media/press-releases/2018/interim-report-january-march-2018/2018-05-03https://www.camurus.com/media/press-releases/2018/camurus-regains-worldwide-development-and-commercialization-rights-to-cam2029-and-related-product-candidates/2018-05-03https://www.camurus.com/media/press-releases/2018/notice-of-annual-general-meeting-2018-in-camurus-ab-publ/2018-03-23https://www.camurus.com/media/press-releases/2018/camurus-annual-report-for-2017/2018-03-22https://www.camurus.com/media/press-releases/2018/camurus-to-present-at-the-cowen-and-company-annual-healthcare-conference-2018/2018-03-08https://www.camurus.com/media/press-releases/2018/full-year-report-2017/2018-02-15https://www.camurus.com/media/press-releases/2018/fda-issues-complete-response-letter-for-cam2038-for-opioid-use-disorder/2018-01-21https://www.camurus.com/media/press-releases/2017/first-cohort-dosed-in-phase-1-clinical-study-of-sustained-release-treprostinil-injection-for-treatment-of-pah/2017-12-21https://www.camurus.com/media/press-releases/2017/camurus-to-present-at-jefferies-2017-london-healthcare-conference/2017-11-07https://www.camurus.com/media/press-releases/2017/camurus-announces-that-fda-advisory-committee-recommends-approval-of-cam2038-for-treatment-of-opioid-use-disorder/2017-11-01https://www.camurus.com/media/press-releases/2017/camurus-announces-that-fda-has-posted-briefing-material-for-cam2038-advisory-committee-meeting/2017-10-30https://www.camurus.com/media/press-releases/2017/interim-report-january-september-2017/2017-10-26https://www.camurus.com/media/press-releases/2017/nomination-committee-appointed-in-respect-of-agm-2018-in-camurus/2017-10-20https://www.camurus.com/media/press-releases/2017/camurus-announces-european-medicines-agency-validation-of-cam2038-marketing-authorization-application-for-treatment-of-opioid-dependence/2017-09-29https://www.camurus.com/media/press-releases/2017/camurus-announces-that-fda-grants-priority-review-of-nda-for-weekly-and-monthly-cam2038-buprenorphine-depots-for-treatment-of-opioid-use-disorder/2017-09-18https://www.camurus.com/media/press-releases/2017/camurus-and-braeburn-announce-submission-of-nda-for-long-acting-buprenorphine-cam2038-for-opioid-use-disorder/2017-07-20https://www.camurus.com/media/press-releases/2017/interim-report-january-june-2017/2017-07-13https://www.camurus.com/media/press-releases/2017/camurus-and-braeburn-pharmaceuticals-announce-topline-phase-2-results-for-long-acting-buprenorphine-in-opioid-dependent-patients-with-chronic-pain/2017-07-12https://www.camurus.com/media/press-releases/2017/rhythm-and-camurus-announce-positive-initial-data-for-extended-release-delivery-of-setmelanotide-for-treatment-of-rare-genetic-disorders-of-obesity/2017-06-27https://www.camurus.com/media/press-releases/2017/long-acting-buprenorphine-blocks-opioid-effects-and-suppresses-withdrawal-symptoms-in-adults-with-opioid-use-disorder/2017-06-22https://www.camurus.com/media/press-releases/2017/camurus-and-braeburn-pharmaceuticals-announce-presentations-of-pivotal-clinical-study-data-of-long-acting-buprenorphine/2017-06-15https://www.camurus.com/media/press-releases/2017/resolutions-at-the-annual-general-meeting-2017-in-camurus/2017-05-03https://www.camurus.com/media/press-releases/2017/interim-report-january-march-2017/2017-05-03https://www.camurus.com/media/press-releases/2017/camurus-and-braeburn-pharmaceuticals-announce-positive-top-line-results-from-long-term-phase-3-safety-study-of-cam2038/2017-05-02https://www.camurus.com/media/press-releases/2017/camurus-appoints-vp-corporate-development--general-counsel/2017-03-31https://www.camurus.com/media/press-releases/2017/camurus-annual-report-for-2016-released/2017-03-30https://www.camurus.com/media/press-releases/2017/notice-of-annual-general-meeting-2017-in-camurus-ab-publ/2017-03-30https://www.camurus.com/media/press-releases/2017/ethypharm-and-camurus-sign-agreement-for-distribution-of-episil-in-france/2017-03-09https://www.camurus.com/media/press-releases/2017/full-year-report-2016/2017-02-16https://www.camurus.com/media/press-releases/2017/camurus-to-present-at-the-cowen-and-company-annual-healthcare-conference-2017/2017-02-02https://www.camurus.com/media/press-releases/2017/camurus-to-present-at-the-jp-morgan-annual-healthcare-conference-2017/2017-01-09https://www.camurus.com/media/press-releases/2016/camurus-capital-markets-and-rd-day-2016/2016-12-14https://www.camurus.com/media/press-releases/2016/program-for-camurus-capital-markets-and-rd-day-14-december-2016/2016-11-25https://www.camurus.com/media/press-releases/2016/braeburn-pharmaceuticals-and-camurus-announce-positive-top-line-phase-3-results-for-long-acting-buprenorphine-for-treatment-of-opioid-addiction/2016-11-14https://www.camurus.com/media/press-releases/2016/camurus-to-provide-an-update-on-the-progress-of-its-research-and-development-programs-at-the-jefferies-2016-healthcare-conference/2016-11-11https://www.camurus.com/media/press-releases/2016/interim-report-january-september-2016/2016-11-08https://www.camurus.com/media/press-releases/2016/camurus-to-host-a-capital-markets-day-14-december-2016/2016-11-01https://www.camurus.com/media/press-releases/2016/nomination-committee-appointed-in-respect-of-agm-2017-in-camurus/2016-10-28https://www.camurus.com/media/press-releases/2016/braeburn-pharmaceuticals-and-camurus-expand-collaboration-and-license-agreement-to-include-new-combination-product-for-pain-and-nausea/2016-10-24https://www.camurus.com/media/press-releases/2016/braeburn-pharmaceuticals-and-camurus-announce-the-presentation-of-new-data-from-clinical-studies-of-long-acting-buprenorphine/2016-10-21https://www.camurus.com/media/press-releases/2016/braeburn-pharmaceuticals-and-camurus-enroll-first-patients-in-a-phase-3-efficacy-trial-of-cam2038-for-treatment-of-chronic-low-back-pain/2016-09-30https://www.camurus.com/media/press-releases/2016/interim-report-january-june-2016/2016-07-14https://www.camurus.com/media/press-releases/2016/camurus-announces-completion-of-phase-2-study-of-cam2029-in-patients-with-acromegaly-and-neuroendocrine-tumors/2016-07-12https://www.camurus.com/media/press-releases/2016/camurus-announces-results-from-a-phase-2-trial-of-cam2032-in-patients-with-prostate-cancer/2016-06-21https://www.camurus.com/media/press-releases/2016/richard-jameson-assumes-position-as-camurus-chief-commercial-officer/2016-06-20https://www.camurus.com/media/press-releases/2016/camurus-interim-report-january-march-2016/2016-05-17https://www.camurus.com/media/press-releases/2016/braeburn-pharmaceuticals-and-camurus-announce-positive-results-from-phase-2-opioid-challenge-study-with-cam2038-in-subjects-with-opioid-use-disorder/2016-05-11https://www.camurus.com/media/press-releases/2016/resolutions-at-the-annual-general-meeting-2016-in-camurus/2016-05-03https://www.camurus.com/media/press-releases/2016/distribution-agreement-signed-with-r-pharm-us-for-episil/2016-04-21https://www.camurus.com/media/press-releases/2016/braeburn-pharmaceuticals-and-camurus-announce-enrollment-goals-reached-in-two-pivotal-phase-3-trials-of-cam2038-for-treatment-of-opioid-dependence/2016-04-05https://www.camurus.com/media/press-releases/2016/notice-of-annual-general-meeting-2016-and-proposal-for-new-incentive-program-in-camurus-ab-publ/2016-03-30https://www.camurus.com/media/press-releases/2016/camurus-annual-report-for-2015-released/2016-03-30https://www.camurus.com/media/press-releases/2016/braeburn-and-camurus-announce-initiation-of-a-phase-2-study-in-opioid-dependent-patients-with-moderate-to-severe-chronic-pain/2016-02-22https://www.camurus.com/media/press-releases/2016/full-year-report-january-december-2015/2016-02-17https://www.camurus.com/media/press-releases/2016/nomination-committee-appointed-in-respect-of-agm-2016-in-camurus/2016-02-04https://www.camurus.com/media/press-releases/2016/rhythm-and-camurus-announce-license-agreement-for-extended-release-fluidcrystal-setmelanotide/2016-01-05https://www.camurus.com/media/press-releases/2015/braeburn-pharmaceuticals-and-camurus-enroll-first-patient-in-a-phase-3-efficacy-trial-of-long-acting-treatment-for-opioid-dependence/2015-12-30https://www.camurus.com/media/press-releases/2015/change-in-the-number-of-shares-and-votes-in-camurus/2015-12-30https://www.camurus.com/media/press-releases/2015/braeburn-pharmaceuticals-and-camurus-announce-start-of-phase-3-trial-of-long-acting-buprenorphine-treatments-for-opioid-dependence/2015-12-15https://www.camurus.com/media/press-releases/2015/camurus-appoints-chief-commercial-officer/2015-12-14https://www.camurus.com/media/press-releases/2015/exercise-of-the-over-allotment-option-in-the-initial-public-offering-of-camurus/2015-12-10https://www.camurus.com/media/press-releases/2015/final-price-in-camuruss-initial-public-offering-set-at-sek-57-per-share--trading-on-nasdaq-stockholm-commences-today/2015-12-03https://www.camurus.com/media/press-releases/2015/camurus-announces-initial-public-offering-on-nasdaq-stockholm/2015-11-19https://www.camurus.com/media/press-releases/2015/camurus-announces-initial-public-offering-on-nasdaq-stockholm-2015-11-18/2015-11-18https://www.camurus.com/media/press-releases/2015/fda-grants-fast-track-designation-for-development-of-cam2038-long-acting-buprenorphine-injections-to-treat-opioid-addiction/2015-11-04https://www.camurus.com/media/press-releases/2015/camurus-ab-interim-report-january---september-2015/2015-10-22https://www.camurus.com/media/press-releases/2015/solasia-acquires-exclusive-license-and-distribution-rights-from-camurus-for-episil-oral-liquid-in-japan-and-china/2015-03-30https://www.camurus.com/media/press-releases/2014/camurus-and-braeburn-pharmaceuticals-sign-exclusive-license-for-long-acting-buprenorphine-injectables-for-the-treatment-of-opioid-dependence-and-pain/2014-11-20https://www.camurus.com/media/media-contact/2025-02-13https://www.camurus.com/media/media-archive/2021-11-02https://www.camurus.com/uk-privacy-notice/2022-06-15https://www.camurus.com/uk-joint-working/2022-06-28https://www.camurus.com/career/2026-03-27https://www.camurus.com/career/daniel-mate/2022-04-27https://www.camurus.com/career/lina-akesson/2022-04-27https://www.camurus.com/career/carola-seibold/2022-04-27https://www.camurus.com/career/daniel-corbee/2022-04-27https://www.camurus.com/contact/2025-07-15https://www.camurus.com/us/2025-04-07https://www.camurus.com/us/about-us/2024-11-13https://www.camurus.com/us/about-us/us-leadership-team/2025-09-04https://www.camurus.com/us/about-us/our-commitment/2024-11-13https://www.camurus.com/us/about-us/responsibility/2024-11-13https://www.camurus.com/us/science/2025-01-17https://www.camurus.com/us/science/products/2025-01-17https://www.camurus.com/us/science/rd-pipeline/2025-07-03https://www.camurus.com/us/science/technology/2025-05-02https://www.camurus.com/us/science/medical-congresses-and-events/2026-03-12https://www.camurus.com/us/disease-area/2024-11-13https://www.camurus.com/us/disease-area/acromegaly/2026-03-23https://www.camurus.com/us/disease-area/polycystic-liver-disease/2025-01-17https://www.camurus.com/us/disease-area/neuroendocrine-tumors/2025-11-14https://www.camurus.com/us/disease-area/opioid-use-disorder/2025-01-17https://www.camurus.com/us/sustainability/2025-12-09https://www.camurus.com/us/partnering/2024-11-13https://www.camurus.com/us/career/2026-03-23https://www.camurus.com/us/contact/2025-03-17https://www.camurus.com/us/privacy-notice/2026-03-23https://www.camurus.com/us/cookie-policy/2026-03-23https://www.camurus.com/us/terms-of-use/2025-03-19https://www.camurus.com/us/consumer-health-data-policy/2025-03-25https://www.camurus.com/us/sign-up/acromegaly-sign-up/2025-07-09https://www.camurus.com/us/sign-up/neuroendocrine-tumor-sign-up/2025-07-09https://www.camurus.com/sv/2026-03-31https://www.camurus.com/sv/integritetspolicy/2026-03-23https://www.camurus.com/sv/om-oss/2026-01-08https://www.camurus.com/sv/om-oss/vart-uppdrag/2024-03-28https://www.camurus.com/sv/om-oss/affarsmodell/2025-08-22https://www.camurus.com/sv/om-oss/styrelse/2021-10-15https://www.camurus.com/sv/om-oss/styrelse/per-olof-wallstrom/2025-05-23https://www.camurus.com/sv/om-oss/styrelse/fredrik-tiberg/2026-03-09https://www.camurus.com/sv/om-oss/styrelse/hege-hellstrom/2026-02-19https://www.camurus.com/sv/om-oss/styrelse/jakob-lindberg/2025-05-23https://www.camurus.com/sv/om-oss/styrelse/stefan-persson/2025-05-23https://www.camurus.com/sv/om-oss/styrelse/erika-soderberg-johnsson/2025-05-23https://www.camurus.com/sv/om-oss/styrelse/hege-hellstrom-2/2025-11-06https://www.camurus.com/sv/om-oss/styrelse/elisabeth-bjork/2026-02-19https://www.camurus.com/sv/om-oss/ledningsgrupp/2021-10-15https://www.camurus.com/sv/om-oss/ledningsgrupp/fredrik-tiberg/2026-03-05https://www.camurus.com/sv/om-oss/ledningsgrupp/anders-vadsholt/2025-07-18https://www.camurus.com/sv/om-oss/ledningsgrupp/jane-buus-laursen/2026-03-24https://www.camurus.com/sv/om-oss/ledningsgrupp/richard-jameson/2025-07-01https://www.camurus.com/sv/om-oss/ledningsgrupp/agneta-svedberg/2025-09-25https://www.camurus.com/sv/om-oss/ledningsgrupp/annette-mattsson/2025-07-01https://www.camurus.com/sv/om-oss/ledningsgrupp/fredrik-joabsson/2025-08-20https://www.camurus.com/sv/om-oss/ledningsgrupp/maria-lundqvist/2025-09-25https://www.camurus.com/sv/om-oss/ledningsgrupp/alberto-m-pedroncelli/2025-07-01https://www.camurus.com/sv/om-oss/ledningsgrupp/susanne-lagerlund/2026-03-31https://www.camurus.com/sv/om-oss/ledningsgrupp/markus-johnsson/2025-09-25https://www.camurus.com/sv/om-oss/ledningsgrupp/behshad-sheldon/2025-07-01https://www.camurus.com/sv/om-oss/ledningsgrupp/bo-a-c-tarras-wahlberg/2025-07-01https://www.camurus.com/sv/om-oss/uppforandekod/2025-09-01https://www.camurus.com/sv/om-oss/uppforandekod-leverantorer/2024-09-11https://www.camurus.com/sv/vetenskap/2025-12-12https://www.camurus.com/sv/vetenskap/produkter/2025-08-14https://www.camurus.com/sv/vetenskap/rd-pipeline/2025-08-13https://www.camurus.com/sv/vetenskap/teknologi/2025-08-13https://www.camurus.com/sv/vetenskap/medical-hub/2025-12-12https://www.camurus.com/sv/terapiomraden/2025-11-24https://www.camurus.com/sv/terapiomraden/opioidberoende/2025-12-12https://www.camurus.com/sv/terapiomraden/akromegali/2025-12-12https://www.camurus.com/sv/terapiomraden/neuroendokrina-tumorer/2025-08-13https://www.camurus.com/sv/terapiomraden/polycystisk-leversjukdom/2025-08-13https://www.camurus.com/sv/terapiomraden/berattelser/melissas-berattelse/2021-11-16https://www.camurus.com/sv/terapiomraden/berattelser/wills-berattelse/2021-11-16https://www.camurus.com/sv/terapiomraden/berattelser/johns-berattelse/2021-11-16https://www.camurus.com/sv/terapiomraden/berattelser/lauras-berattelse/2021-11-16https://www.camurus.com/sv/terapiomraden/berattelser/antonios-berattelse/2021-11-16https://www.camurus.com/sv/terapiomraden/berattelser/kens-berattelse/2021-11-16https://www.camurus.com/sv/terapiomraden/berattelser/daniels-berattelse/2021-11-16https://www.camurus.com/sv/terapiomraden/berattelser/crys-berattelse/2021-11-16https://www.camurus.com/sv/terapiomraden/berattelser/angelikis-berattelse/2024-10-28https://www.camurus.com/sv/terapiomraden/berattelser/joshs-berattelse/2023-07-05https://www.camurus.com/sv/terapiomraden/berattelser/kaths-berattelse/2023-07-05https://www.camurus.com/sv/terapiomraden/berattelser/richards-berattelse/2025-10-06https://www.camurus.com/sv/terapiomraden/berattelser/maries-och-ryans-berattelse/2025-10-06https://www.camurus.com/sv/terapiomraden/berattelser/darros-berattelse/2025-10-16https://www.camurus.com/sv/terapiomraden/berattelser/mattias-berattelse/2025-11-24https://www.camurus.com/sv/terapiomraden/berattelser/cullans-berattelse/2025-11-24https://www.camurus.com/sv/hallbarhet/2025-11-12https://www.camurus.com/sv/hallbarhet/transparensrapportering/2026-03-18https://www.camurus.com/sv/hallbarhet/patienter/2025-07-07https://www.camurus.com/sv/hallbarhet/patienter/tillgang-till-lakemedel/2025-05-08https://www.camurus.com/sv/hallbarhet/patienter/kliniska-studier/2024-10-01https://www.camurus.com/sv/hallbarhet/medarbetare/2026-02-27https://www.camurus.com/sv/hallbarhet/miljo/2025-11-19https://www.camurus.com/sv/hallbarhet/miljo/handlingsplan-for-klimatneutralitet/2025-11-19https://www.camurus.com/sv/hallbarhet/ansvarsfullt-foretagande/2025-08-13https://www.camurus.com/sv/hallbarhet/styrdokument/2026-03-26https://www.camurus.com/sv/hallbarhet/sdg-analys/2026-01-28https://www.camurus.com/sv/hallbarhet/rankningar/2025-12-15https://www.camurus.com/sv/hallbarhet/hallbarhetsmal/2026-02-27https://www.camurus.com/sv/anvandningsvillkor/2021-11-29https://www.camurus.com/sv/cookiepolicy/2026-03-18https://www.camurus.com/sv/investerare/2026-03-17https://www.camurus.com/sv/investerare/aktien/2026-03-05https://www.camurus.com/sv/investerare/kalender/2026-01-26https://www.camurus.com/sv/investerare/presentationer/2026-03-06https://www.camurus.com/sv/investerare/finansiella-rapporter/2019-10-04https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-delarsrapport-andra-kvartalet-2024/2024-07-16https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-delarsrapport-tredje-kvartalet-2024/2024-11-07https://www.camurus.com/sv/investerare/finansiella-rapporter/delarsrapport-januari-juni-2017/2017-07-13https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-ab-delarsrapport-januari---september-2015/2015-10-22https://www.camurus.com/sv/investerare/finansiella-rapporter/bokslutskommunike-2017/2018-02-15https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-delarsrapport-januari-september-2019/2019-11-08https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-bokslutskommunike-2021/2022-02-16https://www.camurus.com/sv/investerare/finansiella-rapporter/bokslutskommunike-2016/2017-02-16https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-bokslutskommunike-2020/2021-02-11https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-delarsrapport-januari-mars-2019/2019-05-09https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-delarsrapport-januari-mars-2024/2024-05-13https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-arsredovisning-for-2023/2024-03-28https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-bokslutskommunike-2023/2024-02-15https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-delarsrapport-andra-kvartalet-2021/2021-07-15https://www.camurus.com/sv/investerare/finansiella-rapporter/delarsrapport-januari-mars-2018/2018-05-03https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-delarsrapport-januari-mars-2025/2025-05-15https://www.camurus.com/sv/investerare/finansiella-rapporter/delarsrapport-januari-mars-2017/2017-05-03https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-arsredovisningen-for-2015-offentliggjord/2016-03-30https://www.camurus.com/sv/investerare/finansiella-rapporter/delarsrapport-januari-september-2017/2017-10-26https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-delarsrapport-andra-kvartalet-2020/2020-07-16https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-bokslutskommunike-2024/2025-02-13https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-delarsrapport-januari-mars-2021/2021-05-06https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-arsredovisning-for-2020/2021-04-14https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-delarsrapport-januari-mars-2020/2020-05-07https://www.camurus.com/sv/investerare/finansiella-rapporter/delarsrapport-januari-juni-2016/2016-07-14https://www.camurus.com/sv/investerare/finansiella-rapporter/bokslutskommunike-januari-december-2015/2016-02-17https://www.camurus.com/sv/investerare/finansiella-rapporter/bokslutskommunike-2018/2019-02-06https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-arsredovisning-for-2022/2023-03-30https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-arsredovisning-for-2018/2019-04-15https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-bokslutskommunike-2022/2023-02-14https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-delarsrapport-tredje-kvartalet-2020/2020-11-05https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-delarsrapport-januari-mars-2023/2023-05-10https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-delarsrapport-tredje-kvartalet-2022/2022-11-10https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-delarsrapport-januari-juni-2019/2019-07-18https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-arsredovisning-for-2017/2018-03-22https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-arsredovisning-for-2021/2022-04-06https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-delarsrapport-januari-mars-2022/2022-05-12https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-delarsrapport-andra-kvartalet-2022/2022-07-15https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-arsredovisning-for-2019/2020-04-08https://www.camurus.com/sv/investerare/finansiella-rapporter/delarsrapport-januari-september-2018/2018-10-25https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-delarsrapport-tredje-kvartalet-2023/2023-11-09https://www.camurus.com/sv/investerare/finansiella-rapporter/delarsrapport-januari-juni-2018/2018-07-17https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-delarsrapport-andra-kvartalet-2023/2023-07-18https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-arsredovisning-for-2016-publicerad/2017-03-30https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-bokslutskommunike-2019/2020-02-12https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-delarsrapport-januari-mars-2016/2016-05-17https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-delarsrapport-tredje-kvartalet-2021/2021-11-04https://www.camurus.com/sv/investerare/finansiella-rapporter/delarsrapport-januari-september-2016/2016-11-08https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-bokslutskommunike-2025/2026-02-24https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-delarsrapport-andra-kvartalet-2025/2025-07-17https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-arsredovisning-for-2024/2025-04-30https://www.camurus.com/sv/investerare/finansiella-rapporter/camurus-delarsrapport-tredje-kvartalet-2025/2025-11-06https://www.camurus.com/sv/investerare/analytiker/2026-02-12https://www.camurus.com/sv/investerare/bolagsstyrning/2025-04-30https://www.camurus.com/sv/investerare/bolagsstyrning/kommiteer/2024-05-16https://www.camurus.com/sv/investerare/bolagsstyrning/ersattningar/2025-06-10https://www.camurus.com/sv/investerare/bolagsstyrning/bolagsstammor/2021-10-28https://www.camurus.com/sv/investerare/bolagsstyrning/revisorer/2024-05-16https://www.camurus.com/sv/investerare/bolagsstyrning/incitamentsprogram/2025-07-17https://www.camurus.com/sv/investerare/bolagsstyrning/bolagsordning/2024-05-16https://www.camurus.com/sv/investerare/bolagsstyrning/valberedning/2024-12-11https://www.camurus.com/sv/investerare/bolagsstyrning/bolagsstamma/2026-01-26https://www.camurus.com/sv/investerare/vd-ord/2026-02-12https://www.camurus.com/sv/investerare/ir-kontakt/2025-08-13https://www.camurus.com/sv/investerare/prenumeration/2023-07-07https://www.camurus.com/sv/partnerskap/2025-08-13https://www.camurus.com/sv/media/2019-10-02https://www.camurus.com/sv/media/pressmeddelanden/2019-10-02https://www.camurus.com/sv/media/pressmeddelanden/2026/forandring-av-antalet-aktier-och-roster-i-camurus-2026-03-31/2026-03-31https://www.camurus.com/sv/media/pressmeddelanden/2026/camurus-ansokan-om-marknadsgodkannande-av-oclaiz-for-behandling-av-akromegali-accepterad-for-granskning-av-fda/2026-01-09https://www.camurus.com/sv/media/pressmeddelanden/2026/camurus-bokslutskommunike-2025/2026-02-12https://www.camurus.com/sv/media/pressmeddelanden/2026/forandring-av-antalet-aktier-och-roster-i-camurus-2026-02-27/2026-02-27https://www.camurus.com/sv/media/pressmeddelanden/2026/jane-buus-laursen-utsedd-till-chief-corporate-development-officer-pa-camurus/2026-02-17https://www.camurus.com/sv/media/pressmeddelanden/2025/beslut-vid-camurus-arsstamma-2025/2025-05-27https://www.camurus.com/sv/media/pressmeddelanden/2025/camurus-presenterar-vid-jefferies-global-healthcare-conference/2025-05-22https://www.camurus.com/sv/media/pressmeddelanden/2025/camurus-delarsrapport-januari-mars-2025/2025-05-15https://www.camurus.com/sv/media/pressmeddelanden/2025/anders-vadsholt-utsedd-till-chief-financial-officer-pa-camurus/2025-05-14https://www.camurus.com/sv/media/pressmeddelanden/2025/camurus-lanserar-buvidal-vecko-och-manadsdepa-i-portugal/2025-05-08https://www.camurus.com/sv/media/pressmeddelanden/2025/chmp-rekommenderar-godkannande-av-oczyesa-for-behandling-av-akromegali-i-eu/2025-04-25https://www.camurus.com/sv/media/pressmeddelanden/2025/camurus-styrelse-utnyttjar-aterkopsbemyndigande-for-sakerstallande-av-bolagets-ataganden-enligt-prestationsaktieprogram-20252028/2025-05-27https://www.camurus.com/sv/media/pressmeddelanden/2025/camurus-vd-fredrik-tiberg-tilldelas-the-arthur-d-little-nordic-life-science-award/2025-03-19https://www.camurus.com/sv/media/pressmeddelanden/2025/camurus-tilldelas-utmarkelsen-ethifinance-esg-platinum/2025-03-14https://www.camurus.com/sv/media/pressmeddelanden/2025/jon-garay-alonso-lamnar-tjansten-som-camurus-cfo/2025-03-03https://www.camurus.com/sv/media/pressmeddelanden/2025/camurus-bokslutskommunike-2024/2025-02-13https://www.camurus.com/sv/media/pressmeddelanden/2025/camurus-resultat-for-fjarde-kvartalet-och-helaret-2024-hogre-an-tidigare-estimat/2025-01-23https://www.camurus.com/sv/media/pressmeddelanden/2025/buvidal-vecko-och-manadsdepa-nu-tillganglig-for-patienter-i-schweiz/2025-01-17https://www.camurus.com/sv/media/pressmeddelanden/2025/camurus-oczyesa-har-godkants-for-behandling-av-akromegali-i-storbritannien/2025-08-28https://www.camurus.com/sv/media/pressmeddelanden/2025/camurus-tilldelas-esg-klassificeringen-lag-risk-av-sustainalytics/2025-08-20https://www.camurus.com/sv/media/pressmeddelanden/2025/camurus-vd-saljer-aktier/2025-07-24https://www.camurus.com/sv/media/pressmeddelanden/2025/camurus-delarsrapport-andra-kvartalet-2025/2025-07-17https://www.camurus.com/sv/media/pressmeddelanden/2025/camurus-meddelar-eu-godkannande-av-oczyesa-for-behandling-av-akromegali/2025-07-01https://www.camurus.com/sv/media/pressmeddelanden/2025/forandring-av-antalet-aktier-och-roster-i-camurus/2025-06-30https://www.camurus.com/sv/media/pressmeddelanden/2025/camurus-studie-positano-visar-behandlingseffekt-av-cam2029-i-patienter-med-polycystisk-leversjukdom/2025-06-18https://www.camurus.com/sv/media/pressmeddelanden/2025/inlosen-i-camurus-personaloptionsprogram-20222026/2025-09-15https://www.camurus.com/sv/media/pressmeddelanden/2025/camurus-och-lilly-ingar-samarbets-och-licensavtal-avseende-langtidsverkande-inkretiner-baserade-pa-fluidcrystal/2025-06-03https://www.camurus.com/sv/media/pressmeddelanden/2025/camurus-lanserar-langtidsverkande-oczyesa-for-behandling-av-akromegali/2025-11-03https://www.camurus.com/sv/media/pressmeddelanden/2025/camurus-erhaller-hogsta-niva-i-certifiering-fran-my-green-lab/2025-11-04https://www.camurus.com/sv/media/pressmeddelanden/2025/camurus-delarsrapport-tredje-kvartalet-2025/2025-11-06https://www.camurus.com/sv/media/pressmeddelanden/2025/forandring-av-antalet-aktier-och-roster-i-camurus-2025-12-30/2025-12-30https://www.camurus.com/sv/media/pressmeddelanden/2025/forandring-av-antalet-aktier-och-roster-i-camurus-2025-09-30/2025-09-30https://www.camurus.com/sv/media/pressmeddelanden/2025/camurus-lamnar-in-sin-forsta-cdp-rapportering/2025-09-19https://www.camurus.com/sv/media/pressmeddelanden/2025/camurus-rapporterar-positiva-resultat-for-cam2056-semaglutid-manadsdepa/2025-11-10https://www.camurus.com/sv/media/pressmeddelanden/2025/camurus-presenterar-vid-jefferies-london-healthcare-conference/2025-11-12https://www.camurus.com/sv/media/pressmeddelanden/2025/valberedning-utsedd-infor-camurus-arsstamma-2026/2025-11-13https://www.camurus.com/sv/media/pressmeddelanden/2025/forandring-av-antalet-aktier-och-roster-i-camurus-2025-11-28/2025-11-28https://www.camurus.com/sv/media/pressmeddelanden/2025/camurus-och-gubra-ingar-samarbets-och-licensavtal-for-utveckling-av-langtidsverkande-behandling-for-hypoparatyreoidism/2025-12-16https://www.camurus.com/sv/media/pressmeddelanden/2025/camurus-arsredovisning-for-2024/2025-04-30https://www.camurus.com/sv/media/pressmeddelanden/2025/kallelse-till-arsstamma-2025-i-camurus-ab-publ-2025/2025-04-23https://www.camurus.com/sv/media/pressmeddelanden/2024/camurus-bokslutskommunike-2023/2024-02-15https://www.camurus.com/sv/media/pressmeddelanden/2024/forandring-av-antalet-aktier-och-roster-i-camurus/2024-06-28https://www.camurus.com/sv/media/pressmeddelanden/2024/slutford-rekrytering-av-patienter-i-positano-studien-av-cam2029-for-behandling-av-polycystisk-leversjukdom/2024-02-08https://www.camurus.com/sv/media/pressmeddelanden/2024/beshad-sheldon-utses-till-president-for-camurus-inc-/2024-02-13https://www.camurus.com/sv/media/pressmeddelanden/2024/camurus-nda-ansokan-for-oclaiz-for-behandling-av-akromegali-har-accepterats-for-granskning-av-fda/2024-03-05https://www.camurus.com/sv/media/pressmeddelanden/2024/camurus-arsredovisning-for-2023/2024-03-28https://www.camurus.com/sv/media/pressmeddelanden/2024/kallelse-till-arsstamma-2024-i-camurus-ab-publ/2024-04-02https://www.camurus.com/sv/media/pressmeddelanden/2024/camurus-delarsrapport-januari-mars-2024/2024-05-08https://www.camurus.com/sv/media/pressmeddelanden/2024/beslut-vid-camurus-arsstamma-2024/2024-05-08https://www.camurus.com/sv/media/pressmeddelanden/2024/camurus-erhaller-forbattrad-esg-rating-av-msci/2024-10-28https://www.camurus.com/sv/media/pressmeddelanden/2024/inlosen-i-camurus-personaloptionsprogram-20212024/2024-09-19https://www.camurus.com/sv/media/pressmeddelanden/2024/ema-rekommenderar-sarlakemedelsstatus-for-camurus-oktreotid-subkutan-depa-for-behandling-av-polycystisk-leversjukdom/2024-09-20https://www.camurus.com/sv/media/pressmeddelanden/2024/forandring-av-antalet-aktier-och-roster-i-camurus-2024-09-30/2025-06-26https://www.camurus.com/sv/media/pressmeddelanden/2024/camurus-uppdaterar-kring-den-regulatoriska-processen-for-cam2029-for-behandling-av-akromegali-i-usa/2024-10-21https://www.camurus.com/sv/media/pressmeddelanden/2024/camurus-inkluderad-i-fortunes-lista-leading-the-charge-spotlighting-the-25-companies-smashing-the-glass-ceiling/2024-07-25https://www.camurus.com/sv/media/pressmeddelanden/2024/camurus-delarsrapport-tredje-kvartalet-2024/2024-11-07https://www.camurus.com/sv/media/pressmeddelanden/2024/camurus-presenterar-vid-jefferies-london-healthcare-conference/2024-11-11https://www.camurus.com/sv/media/pressmeddelanden/2024/valberedning-utsedd-infor-camurus-arsstamma-2025/2024-11-12https://www.camurus.com/sv/media/pressmeddelanden/2024/camurus-skickar-in-sin-forsta-kommunikation-till-fn-global-compact-och-fornyar-nasdaq-transparency-partner-certifikat/2024-06-24https://www.camurus.com/sv/media/pressmeddelanden/2024/camurus-ansokan-om-marknadsgodkannande-for-oktreotid-manadsdepa-cam2029-for-akromegali-har-accepterats-for-granskning-av-ema/2024-05-23https://www.camurus.com/sv/media/pressmeddelanden/2024/camurus-presenterar-vid-jefferies-2024-healthcare-conference-new-york/2024-05-28https://www.camurus.com/sv/media/pressmeddelanden/2024/camurus-styrelse-utnyttjar-aterkopsbemyndigande-for-sakerstallande-av-bolagets-ataganden-enligt-prestationsaktieprogram-20242027/2024-05-30https://www.camurus.com/sv/media/pressmeddelanden/2024/inlosen-av-camurus-personaloptionsprogram-20212024/2024-06-12https://www.camurus.com/sv/media/pressmeddelanden/2024/ny-publikation-visar-effekt-av-vecko-och-manadsinjektioner-av-buprenorfin-vid-behandling-av-opioidberoende-hos-individer-som-anvander-fentanyl/2024-06-25https://www.camurus.com/sv/media/pressmeddelanden/2024/camurus-meddelar-positiva-fas-3-resultat-fran-acroinnova-2-studien-av-oktreotid-subkutan-depa-cam2029-i-patienter-med-akromegali/2024-07-15https://www.camurus.com/sv/media/pressmeddelanden/2024/camurus-delarsrapport-andra-kvartalet-2024/2024-07-16https://www.camurus.com/sv/media/pressmeddelanden/2024/forandring-av-antalet-aktier-och-roster-i-camurus-2024-12-30/2024-12-30https://www.camurus.com/sv/media/pressmeddelanden/2023/camurus-delarsrapport-tredje-kvartalet-2023/2023-11-09https://www.camurus.com/sv/media/pressmeddelanden/2023/camurus-etablerar-nytt-hallbart-huvudkontor-och-forskningslabb-i-science-village-lund/2023-09-26https://www.camurus.com/sv/media/pressmeddelanden/2023/valberedning-utsedd-infor-camurus-arsstamma-2024/2023-10-18https://www.camurus.com/sv/media/pressmeddelanden/2023/camurus-hojer-finansiella-utsikten-for-helaret-2023/2023-10-23https://www.camurus.com/sv/media/pressmeddelanden/2023/camurus-presenterar-vid-jefferies-2023-healthcare-conference-london/2023-11-01https://www.camurus.com/sv/media/pressmeddelanden/2023/camurus-erhaller-forbattrad-esg-rankning-fran-sustainalytics/2023-11-06https://www.camurus.com/sv/media/pressmeddelanden/2023/slutford-rekrytering-av-patienter-i-camurus-fas-3-studie-sorento-av-cam2029-for-behandling-av-neuroendokrina-tumorer/2023-12-14https://www.camurus.com/sv/media/pressmeddelanden/2023/camurus-flyttar-till-nasdaq-stockholm-large-cap/2023-12-20https://www.camurus.com/sv/media/pressmeddelanden/2023/camurus-skickar-in-ansokan-till-fda-om-marknadsgodkannande-for-oclaiz-for-behandling-av-akromegali/2023-12-21https://www.camurus.com/sv/media/pressmeddelanden/2023/forandring-av-antalet-aktier-och-roster-i-camurus-2023-12-29/2023-12-29https://www.camurus.com/sv/media/pressmeddelanden/2023/camurus-meddelar-nya-fas-3-data-som-styrker-langtidssakerhet-och-behandlingseffekt-av-oktreotid-subkutan-depa-cam2029-i-patienter-med-akromegali/2023-07-17https://www.camurus.com/sv/media/pressmeddelanden/2023/camurus-meddelar-fda-godkannande-av-brixadi-for-behandling-av-opioidberoende/2023-05-23https://www.camurus.com/sv/media/pressmeddelanden/2023/camurus-presenterar-vid-jefferies-2023-healthcare-conference-new-york/2023-05-29https://www.camurus.com/sv/media/pressmeddelanden/2023/forandring-av-antalet-aktier-och-roster-i-camurus/2023-05-31https://www.camurus.com/sv/media/pressmeddelanden/2023/camurus-antagen-som-medlem-i-fn-global-compact/2023-06-19https://www.camurus.com/sv/media/pressmeddelanden/2023/camurus-oktreotid-subkutan-depa-cam2029-visar-positiva-resultat-i-placebokontrollerad-fas-3-studie-i-patienter-med-akromegali/2023-06-20https://www.camurus.com/sv/media/pressmeddelanden/2023/beslut-vid-camurus-arsstamma-2023/2023-05-10https://www.camurus.com/sv/media/pressmeddelanden/2023/inlosen-av-camurus-teckningsoptionsprogram-20202023/2023-08-25https://www.camurus.com/sv/media/pressmeddelanden/2023/forandring-av-antalet-aktier-och-roster-i-camurus-2023-08-31/2023-08-31https://www.camurus.com/sv/media/pressmeddelanden/2023/camurus-meddelar-lansering-av-brixadi-i-usa-for-behandling-av-opioidberoende/2023-09-05https://www.camurus.com/sv/media/pressmeddelanden/2023/camurus-arsredovisning-for-2022/2023-03-30https://www.camurus.com/sv/media/pressmeddelanden/2023/camurus-drar-tillbaka-andringsansokan-for-cam2038-till-att-omfatta-kronisk-smarta/2023-02-13https://www.camurus.com/sv/media/pressmeddelanden/2023/camurus-bokslutskommunike-2022/2023-02-14https://www.camurus.com/sv/media/pressmeddelanden/2023/kallelse-till-arsstamma-2023-i-camurus-ab-publ/2023-04-04https://www.camurus.com/sv/media/pressmeddelanden/2023/alberto-pedroncelli-utses-till-medicinsk-chef-pa-camurus/2023-04-04https://www.camurus.com/sv/media/pressmeddelanden/2023/camurus-delarsrapport-januari-mars-2023/2023-05-10https://www.camurus.com/sv/media/pressmeddelanden/2023/camurus-delarsrapport-andra-kvartalet-2023/2023-07-18https://www.camurus.com/sv/media/pressmeddelanden/2022/kallelse-till-arsstamma-2022-i-camurus-ab-publ/2022-04-06https://www.camurus.com/sv/media/pressmeddelanden/2022/forandring-av-antalet-aktier-och-roster-i-camurus-2022-08-31/2022-08-31https://www.camurus.com/sv/media/pressmeddelanden/2022/uppdatering-av-forandring-av-antalet-aktier-och-roster-i-camurus/2022-08-31https://www.camurus.com/sv/media/pressmeddelanden/2022/camurus-presenterar-uppdaterad-vision-for-tillvaxt-och-finansiella-utsikter-till-2027-pa-kapitalmarknads--och-fou-dag/2022-09-06https://www.camurus.com/sv/media/pressmeddelanden/2022/camurus-arsredovisning-for-2021/2022-04-06https://www.camurus.com/sv/media/pressmeddelanden/2022/valberedning-utsedd-infor-camurus-arsstamma-2023/2022-10-19https://www.camurus.com/sv/media/pressmeddelanden/2022/camurus-stodjer-tva-globala-dagar-for-sallsynta-sjukdomar/2022-10-28https://www.camurus.com/sv/media/pressmeddelanden/2022/camurus-meddelar-att-braeburn-lamnar-in-ansokan-om-marknadsgodkannande-for-brixadi-i-usa/2022-11-23https://www.camurus.com/sv/media/pressmeddelanden/2022/camurus-meddelar-att-fda-aviserat-pdufa-datum-for-brixadi-i-usa/2022-12-08https://www.camurus.com/sv/media/pressmeddelanden/2022/forandring-av-antalet-aktier-och-roster-i-camurus-2022-12-30/2022-12-30https://www.camurus.com/sv/media/pressmeddelanden/2022/solasia-forvarvar-episil-fran-camurus/2022-07-08https://www.camurus.com/sv/media/pressmeddelanden/2022/camurus-delarsrapport-andra-kvartalet-2022/2022-07-15https://www.camurus.com/sv/media/pressmeddelanden/2022/forandring-av-antalet-aktier-och-roster-i-camurus-2022-06-30/2022-06-30https://www.camurus.com/sv/media/pressmeddelanden/2022/inlosen-av-camurus-teckningsoptionsprogram-20192022/2022-08-23https://www.camurus.com/sv/media/pressmeddelanden/2022/camurus-utser-jonas-duborn-till-head-of-compliance/2022-06-14https://www.camurus.com/sv/media/pressmeddelanden/2022/inbjudan-till-camurus-kapitalmarknads--och-fou-dag-6-september-2022/2022-06-10https://www.camurus.com/sv/media/pressmeddelanden/2022/camurus-presenterar-vid-jefferies-2022-healthcare-conference-new-york/2022-06-07https://www.camurus.com/sv/media/pressmeddelanden/2022/forandring-av-antalet-aktier-och-roster-i-camurus/2022-05-31https://www.camurus.com/sv/media/pressmeddelanden/2022/program-for-camurus-kapitalmarknads--och-fou-dag-den-6-september-2022/2022-08-26https://www.camurus.com/sv/media/pressmeddelanden/2022/camurus-stodjer-international-overdose-awareness-day-2022/2022-08-30https://www.camurus.com/sv/media/pressmeddelanden/2022/lipidforskningspris-utdelat-for-banbrytande-innovationer-inom-rna-stabilisering-och-lipidbaserade-formuleringar/2022-04-04https://www.camurus.com/sv/media/pressmeddelanden/2022/camurus-presenterar-vid-jefferies-2022-healthcare-conference-london/2022-11-11https://www.camurus.com/sv/media/pressmeddelanden/2022/beslut-vid-camurus-arsstamma-2022/2022-05-12https://www.camurus.com/sv/media/pressmeddelanden/2022/camurus-bokslutskommunike-2021/2022-02-16https://www.camurus.com/sv/media/pressmeddelanden/2022/camurus-delarsrapport-tredje-kvartalet-2022/2022-11-10https://www.camurus.com/sv/media/pressmeddelanden/2022/camurus-delarsrapport-januari-mars-2022/2022-05-12https://www.camurus.com/sv/media/pressmeddelanden/2022/camurus-meddelar-att-dosering-paborjats-i-fas-3-studie-av-setmelanotid-veckodepa-i-patienter-med-genetiska-fetmasjukdomar/2022-01-13https://www.camurus.com/sv/media/pressmeddelanden/2021/forandring-av-antalet-aktier-och-roster-i-camurus/2021-12-30https://www.camurus.com/sv/media/pressmeddelanden/2021/braeburn-erhaller-nytt-crl-for-brixadi-i-usa/2021-12-15https://www.camurus.com/sv/media/pressmeddelanden/2021/europeiska-lakemedelsmyndigheten-ema-accepterar-ansokan-om-utokad-indikation-for-buvidal-till-att-inkludera-behandling-av-kronisk-smarta/2021-11-30https://www.camurus.com/sv/media/pressmeddelanden/2021/camurus-meddelar-att-dosering-paborjats-i-fas-3-studie-av-cam2029-i-patienter-med-neuroendokrina-tumorer/2021-11-11https://www.camurus.com/sv/media/pressmeddelanden/2021/camurus-delarsrapport-tredje-kvartalet-2021/2021-11-04https://www.camurus.com/sv/media/pressmeddelanden/2021/valberedning-utsedd-infor-camurus-arsstamma-2022/2021-10-27https://www.camurus.com/sv/media/pressmeddelanden/2021/jon-u-garay-alonso-blir-ny-chief-financial-officer-pa-camurus/2021-10-13https://www.camurus.com/sv/media/pressmeddelanden/2021/forandring-av-antalet-aktier-och-roster-i-camurus-2021-09-30/2021-09-30https://www.camurus.com/sv/media/pressmeddelanden/2021/fda-beviljar-sarlakemedelsstatus-i-usa-for-cam2029-for-behandling-av-polycystisk-leversjukdom/2021-09-16https://www.camurus.com/sv/media/pressmeddelanden/2021/camurus-cfo-kommer-att-sluta-i-bolaget/2021-09-15https://www.camurus.com/sv/media/pressmeddelanden/2021/forandring-av-antalet-aktier-och-roster-i-camurus-2021-08-31/2021-08-31https://www.camurus.com/sv/media/pressmeddelanden/2021/camurus-delarsrapport-andra-kvartalet-2021/2021-07-15https://www.camurus.com/sv/media/pressmeddelanden/2021/forandring-av-antalet-aktier-och-roster-i-camurus-2021-06-30/2021-06-30https://www.camurus.com/sv/media/pressmeddelanden/2021/camurus-meddelar-att-fda-aviserat-pdufa-datum-for-brixadi-i-usa/2021-06-26https://www.camurus.com/sv/media/pressmeddelanden/2021/camurus-meddelar-att-braeburn-lamnat-in-ansokan-om-marknadsgodkannande-for-brixadi-i-usa/2021-06-15https://www.camurus.com/sv/media/pressmeddelanden/2021/forandring-av-antalet-aktier-och-roster-i-camurus-2021-05-31/2021-05-31https://www.camurus.com/sv/media/pressmeddelanden/2021/inlosen-av-camurus-teckningsoptionsprogram-20182021/2021-05-21https://www.camurus.com/sv/media/pressmeddelanden/2021/camurus-vinnare-av-carnegie-sustainability-award-2021/2021-05-19https://www.camurus.com/sv/media/pressmeddelanden/2021/camurus-annonserar-publikation-som-visar-hogre-tillfredsstallelse-bland-patienter-vid-behandling-av-opioidberoende-med-buvidal-vecko--och-manadsdepaer/2021-05-10https://www.camurus.com/sv/media/pressmeddelanden/2021/beslut-vid-camurus-arsstamma-2021/2021-05-06https://www.camurus.com/sv/media/pressmeddelanden/2021/camurus-delarsrapport-januari-mars-2021/2021-05-06https://www.camurus.com/sv/media/pressmeddelanden/2021/australiska-lakemedelsmyndigheten-godkanner-viktiga-regulatoriska-uppdateringar-for-buvidal/2021-05-03https://www.camurus.com/sv/media/pressmeddelanden/2021/camurus-arsredovisning-for-2020/2021-04-14https://www.camurus.com/sv/media/pressmeddelanden/2021/kallelse-till-arsstamma-2021-i-camurus-ab-publ/2021-03-30https://www.camurus.com/sv/media/pressmeddelanden/2021/chmp-rekommenderar-godkannande-av-buvidal-160mg-manadsdos-for-behandling-av-opioidberoende/2021-03-26https://www.camurus.com/sv/media/pressmeddelanden/2021/camurus-bokslutskommunike-2020/2021-02-11https://www.camurus.com/sv/media/pressmeddelanden/2021/forandring-av-antalet-aktier-och-roster-i-camurus-2021-01-29/2021-01-29https://www.camurus.com/sv/media/pressmeddelanden/2021/camurus-utser-andrew-mclean-till-vice-president-corporate-development--senior-counsel/2021-01-04https://www.camurus.com/sv/media/pressmeddelanden/2020/forandring-av-antalet-aktier-och-roster-i-camurus/2020-12-30https://www.camurus.com/sv/media/pressmeddelanden/2020/swissmedic-godkanner-buvidal-for-behandling-av-opioidberoende/2020-12-18https://www.camurus.com/sv/media/pressmeddelanden/2020/inlosen-av-camurus-teckningsoptionsprogram-20172020/2020-12-18https://www.camurus.com/sv/media/pressmeddelanden/2020/camurus-meddelar-utfall-i-skiljedomsforfarande-med-braeburn/2020-12-10https://www.camurus.com/sv/media/pressmeddelanden/2020/rattelse-camurus-meddelar-att-braeburn-erhaller-complete-response-letter-for-brixadi-i-usa/2020-12-02https://www.camurus.com/sv/media/pressmeddelanden/2020/camurus-meddelar-att-braeburn-erhaller-complete-response-letter-for-brixadi-i-usa/2020-12-02https://www.camurus.com/sv/media/pressmeddelanden/2020/forandring-av-antalet-aktier-och-roster-i-camurus-2020-11-30/2020-11-30https://www.camurus.com/sv/media/pressmeddelanden/2020/camurus-delarsrapport-tredje-kvartalet-2020/2020-11-05https://www.camurus.com/sv/media/pressmeddelanden/2020/valberedning-utsedd-infor-camurus-arsstamma-2021/2020-10-23https://www.camurus.com/sv/media/pressmeddelanden/2020/forandring-av-antalet-aktier-och-roster-i-camurus-2020-07-31/2020-07-31https://www.camurus.com/sv/media/pressmeddelanden/2020/camurus-delarsrapport-andra-kvartalet-2020/2020-07-16https://www.camurus.com/sv/media/pressmeddelanden/2020/camurus-har-genomfort-en-riktad-nyemission-om-2-miljoner-aktier-och-tillfors-harigenom-300-msek/2020-07-02https://www.camurus.com/sv/media/pressmeddelanden/2020/camurus-avser-att-genomfora-riktad-nyemission-om-cirka-300-msek/2020-07-01https://www.camurus.com/sv/media/pressmeddelanden/2020/positiva-fas-2-resultat-med-fluidcrystal-setmelanotid-veckodepa-for-behandling-av-grav-fetma/2020-06-24https://www.camurus.com/sv/media/pressmeddelanden/2020/camurus-hojer-utsikten-for-produktforsaljning-och-omsattning-2020/2020-06-23https://www.camurus.com/sv/media/pressmeddelanden/2020/braeburn-och-camurus-inleder-skiljedomsforfarande-i-england/2020-06-15https://www.camurus.com/sv/media/pressmeddelanden/2020/camurus-meddelar-att-begaran-om-slutgiltigt-marknadsgodkannande-av-brixadi-lamnats-in-i-usa/2020-06-01https://www.camurus.com/sv/media/pressmeddelanden/2020/buvidal-mot-opioidberoende-ingar-i-hogkostnadsskyddet/2020-05-14https://www.camurus.com/sv/media/pressmeddelanden/2020/beslut-vid-camurus-arsstamma-2020/2020-05-07https://www.camurus.com/sv/media/pressmeddelanden/2020/camurus-delarsrapport-januari-mars-2020/2020-05-07https://www.camurus.com/sv/media/pressmeddelanden/2020/camurus-arsredovisning-for-2019/2020-04-08https://www.camurus.com/sv/media/pressmeddelanden/2020/kallelse-till-arsstamma-2020-i-camurus-ab-publ/2020-04-06https://www.camurus.com/sv/media/pressmeddelanden/2020/camurus-meddelar-stor-efterfragan-pa-buvidal-under-forsta-kvartalet/2020-04-02https://www.camurus.com/sv/media/pressmeddelanden/2020/camurus-bokslutskommunike-2019/2020-02-12https://www.camurus.com/sv/media/pressmeddelanden/2019/forandring-av-antalet-aktier-och-roster-i-camurus/2019-12-30https://www.camurus.com/sv/media/pressmeddelanden/2019/camurus-har-genomfort-en-riktad-nyemission-om-cirka-37-miljoner-aktier-och-tillfors-harigenom-cirka-300-msek/2019-12-06https://www.camurus.com/sv/media/pressmeddelanden/2019/camurus-avser-genomfora-riktad-nyemission-om-upp-till-300-msek/2019-12-05https://www.camurus.com/sv/media/pressmeddelanden/2019/camurus-meddelar-signifikant-forbattrade-behandlingsresultat-for-buvidal-jamfort-med-standardbehandling-i-ny-klinisk-studie/2019-11-26https://www.camurus.com/sv/media/pressmeddelanden/2019/camurus-delarsrapport-januari-september-2019/2019-11-08https://www.camurus.com/sv/media/pressmeddelanden/2019/camurus-meddelar-att-fda-bifaller-braeburns-citizen-petition-och-eliminerar-risken-for-ytterligare-blockering-av-brixadi-i-usa/2019-11-08https://www.camurus.com/sv/media/pressmeddelanden/2019/camurus-presenterar-vid-jefferies-2019-london-healthcare-conference/2019-10-21https://www.camurus.com/sv/media/pressmeddelanden/2019/valberedning-utsedd-infor-camurus-arsstamma-2020/2019-10-15https://www.camurus.com/sv/media/pressmeddelanden/2019/australien-subventionerar-camurus-lakemedel-buvidal-for-behandling-av-opioidberoende/2019-08-26https://www.camurus.com/sv/media/pressmeddelanden/2019/camurus-meddelar-positivt-utfall-i-amerikansk-rattsprocess-om-marknadsgodkannande-av-brixadi/2019-07-23https://www.camurus.com/sv/media/pressmeddelanden/2019/camurus-delarsrapport-januari-juni-2019/2019-07-18https://www.camurus.com/sv/media/pressmeddelanden/2019/camurus-och-ra-pharma-ingar-licensavtal-for-langtidsverkande-zilucoplan/2019-07-16https://www.camurus.com/sv/media/pressmeddelanden/2019/camurus-meddelar-att-fda-beviljar-fas-3-studie-av-cam2029-for-behandling-av-akromegali/2019-06-20https://www.camurus.com/sv/media/pressmeddelanden/2019/camurus-meddelar-publicering-av-fas-3-resultat-som-visar-langtidssakerhet-god-effekt-och-hog-tillfredstallelse-bland-patienter-med-opioidberoende/2019-06-04https://www.camurus.com/sv/media/pressmeddelanden/2019/beslut-vid-camurus-arsstamma-2019/2019-05-09https://www.camurus.com/sv/media/pressmeddelanden/2019/camurus-delarsrapport-januari-mars-2019/2019-05-09https://www.camurus.com/sv/media/pressmeddelanden/2019/camurus-presenterar-delarsrapport-januari-mars-2019-den-9-maj/2019-05-07https://www.camurus.com/sv/media/pressmeddelanden/2019/camurus-arsredovisning-for-2018/2019-04-15https://www.camurus.com/sv/media/pressmeddelanden/2019/braeburn-inleder-rattsprocess-for-att-fa-exklusivitet-upphavd-och-begar-omedelbart-marknadsgodkannande-for-brixadi-i-usa/2019-04-09https://www.camurus.com/sv/media/pressmeddelanden/2019/positiva-resultat-for-buvidal-vid-behandling-av-fentanylmissbruk/2019-04-06https://www.camurus.com/sv/media/pressmeddelanden/2019/kallelse-till-arsstamma-2019-i-camurus-ab-publ/2019-04-05https://www.camurus.com/sv/media/pressmeddelanden/2019/forandring-av-antalet-aktier-och-roster-i-camurus-2019-03-29/2019-03-29https://www.camurus.com/sv/media/pressmeddelanden/2019/camurus-foretradesemission-overtecknad/2019-03-27https://www.camurus.com/sv/media/pressmeddelanden/2019/nytt-datum-for-publicering-av-camurus-arsredovisning-2018/2019-03-26https://www.camurus.com/sv/media/pressmeddelanden/2019/camurus-offentliggor-prospekt-avseende-foretradesemissionen/2019-03-08https://www.camurus.com/sv/media/pressmeddelanden/2019/beslut-vid-camurus-extra-bolagsstamma/2019-03-05https://www.camurus.com/sv/media/pressmeddelanden/2019/camurus-offentliggor-villkoren-for-foretradesemissionen/2019-02-28https://www.camurus.com/sv/media/pressmeddelanden/2019/camurus-presenterar-vid-cowen-and-company-annual-healthcare-conference-2019/2019-02-14https://www.camurus.com/sv/media/pressmeddelanden/2019/bokslutskommunike-2018/2019-02-06https://www.camurus.com/sv/media/pressmeddelanden/2019/kallelse-till-extra-bolagsstamma-i-camurus-ab-publ/2019-02-06https://www.camurus.com/sv/media/pressmeddelanden/2019/camurus-fortsatter-kommersialisering-av-buvidal-och-utveckling-av-lakemedelskandidater-genom-en-fullt-garanterad-foretradesemission-om-400-msek/2019-02-06https://www.camurus.com/sv/media/pressmeddelanden/2019/camurus-presenterar-bokslutskommunike-2018-den-6-februari/2019-02-01https://www.camurus.com/sv/media/pressmeddelanden/2019/camurus-presenterar-vid-seb-biotech-seminar-i-stockholm/2019-01-18https://www.camurus.com/sv/media/pressmeddelanden/2019/buvidal-lanserad-som-forsta-langtidsverkande-behandlingen-mot-opioidberoende-i-eu/2019-01-11https://www.camurus.com/sv/media/pressmeddelanden/2018/fda-utfardar-tentativt-godkannande-for-brixadi-cam2038-for-behandling-av-opioidberoende/2018-12-23https://www.camurus.com/sv/media/pressmeddelanden/2018/camurus-kapitalmarknads--och-fou-dag-den-11-december-2018/2018-12-11https://www.camurus.com/sv/media/pressmeddelanden/2018/buvidal-godkand-som-forsta-langtidsverkande-behandling-av-opioidberoende-i-australien/2018-11-28https://www.camurus.com/sv/media/pressmeddelanden/2018/program-for-camurus-kapitalmarknads--och-fou-dag-den-11-december-2018/2018-11-28https://www.camurus.com/sv/media/pressmeddelanden/2018/camurus-far-eu-godkannande-for-buvidal-cam2038-vecko--och-manadsdepaer-mot-opioidberoende/2018-11-22https://www.camurus.com/sv/media/pressmeddelanden/2018/delarsrapport-januari-september-2018/2018-10-25https://www.camurus.com/sv/media/pressmeddelanden/2018/valberedning-utsedd-infor-camurus-arsstamma-2019/2018-10-16https://www.camurus.com/sv/media/pressmeddelanden/2018/camurus-presenterar-vid-jefferies-2018-london-healthcare-conference/2018-10-10https://www.camurus.com/sv/media/pressmeddelanden/2018/spara-datumet-camurus-kapitalmarknads--och-fou-dag-den-11-december-2018/2018-10-09https://www.camurus.com/sv/media/pressmeddelanden/2018/chmp-rekommenderar-godkannande-av-buvidal-cam2038-for-behandling-av-opioidberoende/2018-09-21https://www.camurus.com/sv/media/pressmeddelanden/2018/camurus-meddelar-positiva-fas-3-resultat-for-cam2038-i-patienter-med-kronisk-smarta/2018-09-18https://www.camurus.com/sv/media/pressmeddelanden/2018/delarsrapport-januari-juni-2018/2018-07-17https://www.camurus.com/sv/media/pressmeddelanden/2018/camurus-meddelar-att-fda-aviserat-pdufa-datum-for-cam2038/2018-07-16https://www.camurus.com/sv/media/pressmeddelanden/2018/andring-av-antalet-aktier-och-roster-i-camurus-ab/2018-06-29https://www.camurus.com/sv/media/pressmeddelanden/2018/camurus-har-genomfort-en-riktad-nyemission-om-11-miljoner-aktier-och-tillfors-harigenom-cirka-102-miljoner-kronor/2018-06-29https://www.camurus.com/sv/media/pressmeddelanden/2018/camurus-uppdaterar-investerarsektionen-pa-sin-hemsida/2018-06-28https://www.camurus.com/sv/media/pressmeddelanden/2018/camurus-avser-genomfora-riktad-nyemission-om-ca-100-msek/2018-06-28https://www.camurus.com/sv/media/pressmeddelanden/2018/camurus-och-medison-ingar-kommersialiseringsavtal-for-cam2038-i-israel/2018-06-12https://www.camurus.com/sv/media/pressmeddelanden/2018/camurus-meddelar-positiva-kliniska-fas-1-resultat-for-langtidsverkande-treprostinil-for-behandling-av-pulmonell-arteriell-hypertension/2018-05-31https://www.camurus.com/sv/media/pressmeddelanden/2018/camurus-meddelar-att-en-uppdaterad-registreringsansokan-for-langtidsverkande-buprenorfin-cam2038-lamnats-in-till-fda/2018-05-28https://www.camurus.com/sv/media/pressmeddelanden/2018/camurus-presenterar-vid-jefferies-2018-global-healthcare-conference/2018-05-25https://www.camurus.com/sv/media/pressmeddelanden/2018/jama-internal-medicine-publicerar-positiva-fas-3-resultat-for-camurus-langtidsverkande-buprenorfindepaer/2018-05-14https://www.camurus.com/sv/media/pressmeddelanden/2018/beslut-vid-camurus-arsstamma-2018/2018-05-03https://www.camurus.com/sv/media/pressmeddelanden/2018/delarsrapport-januari-mars-2018/2018-05-03https://www.camurus.com/sv/media/pressmeddelanden/2018/camurus-atertar-de-globala-utvecklings--och-kommersialiseringsrattigheterna-till-cam2029-och-andra-relaterade-produktkandidater/2018-05-03https://www.camurus.com/sv/media/pressmeddelanden/2018/kallelse-till-arsstamma-2018-i-camurus-ab-publ/2018-03-23https://www.camurus.com/sv/media/pressmeddelanden/2018/camurus-arsredovisning-for-2017/2018-03-22https://www.camurus.com/sv/media/pressmeddelanden/2018/camurus-presenterar-vid-cowen-and-company-annual-healthcare-conference-2018/2018-03-08https://www.camurus.com/sv/media/pressmeddelanden/2018/bokslutskommunike-2017/2018-02-15https://www.camurus.com/sv/media/pressmeddelanden/2018/fda-utfardar-complete-response-letter-for-cam2038-mot-opioidberoende/2018-01-21https://www.camurus.com/sv/media/pressmeddelanden/2017/forsta-gruppen-har-doserats-med-langtidsverkande-treprostinilinjektion-i-klinisk-fas-1-studie/2017-12-21https://www.camurus.com/sv/media/pressmeddelanden/2017/camurus-presenterar-vid-jefferies-2017-london-healthcare-conference/2017-11-07https://www.camurus.com/sv/media/pressmeddelanden/2017/camurus-meddelar-att-fda-advisory-committee-rekommenderar-godkannande-av-cam2038-for-behandling-av-opioidberoende-i-usa/2017-11-01https://www.camurus.com/sv/media/pressmeddelanden/2017/camurus-meddelar-att-fda-har-publicerat-informationsmaterial-infor-advisory-committee-mote/2017-10-30https://www.camurus.com/sv/media/pressmeddelanden/2017/delarsrapport-januari-september-2017/2017-10-26https://www.camurus.com/sv/media/pressmeddelanden/2017/valberedning-utsedd-infor-arsstamma-2018-i-camurus/2017-10-20https://www.camurus.com/sv/media/pressmeddelanden/2017/camurus-ansokan-om-marknadsforingstillstand-for-cam2038-mot-opioidberoende-validerad-av-ema/2017-09-29https://www.camurus.com/sv/media/pressmeddelanden/2017/camurus-meddelar-att-fda-beviljar-priority-review-for-cam2038-for-behandling-av-opioidberoende/2017-09-18https://www.camurus.com/sv/media/pressmeddelanden/2017/camurus-och-braeburn-meddelar-att-ansokan-om-marknadsgodkannande-for-langtidsverkande-buprenorfin-cam2038-mot-opiatberoende-ar-inlamnad-till-fda/2017-07-20https://www.camurus.com/sv/media/pressmeddelanden/2017/delarsrapport-januari-juni-2017/2017-07-13https://www.camurus.com/sv/media/pressmeddelanden/2017/camurus-och-braeburn-meddelar-top-line-fas-2-resultat-for-langtidsverkande-buprenorfin-i-opiatberoende-patienter-med-kronisk-smarta/2017-07-12https://www.camurus.com/sv/media/pressmeddelanden/2017/rhythm-och-camurus-meddelar-positiva-resultat-for-langtidsverkande-setmelanotid-for-behandling-av-sallsynt-genetiskt-orsakad-fetma/2017-06-27https://www.camurus.com/sv/media/pressmeddelanden/2017/langtidsverkande-buprenorfin-blockerar-oonskade-opiateffekter-och-dampar-abstinenssymptom-hos-opiatberoende-personer/2017-06-22https://www.camurus.com/sv/media/pressmeddelanden/2017/camurus-och-braeburn-pharmaceuticals-presenterar-nya-data-fran-kliniska-registreringsstudier-av-langtidsverkande-buprenorfin/2017-06-15https://www.camurus.com/sv/media/pressmeddelanden/2017/beslut-vid-camurus-arsstamma-2017/2017-05-03https://www.camurus.com/sv/media/pressmeddelanden/2017/delarsrapport-januari-mars-2017/2017-05-03https://www.camurus.com/sv/media/pressmeddelanden/2017/camurus-och-braeburn-pharmaceuticals-meddelar-positiva-fas-3-resultat-fran-langtidsstudie-av-cam2038/2017-05-02https://www.camurus.com/sv/media/pressmeddelanden/2017/camurus-utser-vp-corporate-development--general-counsel/2017-03-31https://www.camurus.com/sv/media/pressmeddelanden/2017/camurus-arsredovisning-for-2016-publicerad/2017-03-30https://www.camurus.com/sv/media/pressmeddelanden/2017/kallelse-till-arsstamma-2017-i-camurus-ab-publ/2017-03-30https://www.camurus.com/sv/media/pressmeddelanden/2017/camurus-och-ethypharm-tecknar-avtal-for-distribution-av-episil-i-frankrike/2017-03-09https://www.camurus.com/sv/media/pressmeddelanden/2017/bokslutskommunike-2016/2017-02-16https://www.camurus.com/sv/media/pressmeddelanden/2017/camurus-presenterar-vid-cowen-and-company-annual-healthcare-conference-2017/2017-02-02https://www.camurus.com/sv/media/pressmeddelanden/2017/camurus-presenterar-vid-jp-morgan-healthcare-conference-2017/2017-01-09https://www.camurus.com/sv/media/pressmeddelanden/2016/camurus-ab-kapitalmarknads--och-fu-dag-2016/2016-12-14https://www.camurus.com/sv/media/pressmeddelanden/2016/program-for-camurus-kapitalmarknads--och-fu-dag-den-14-december-2016/2016-11-25https://www.camurus.com/sv/media/pressmeddelanden/2016/camurus-och-braeburn-pharmaceuticals-tillkannager-positiva-fas-3-resultat-for-langtidsverkande-buprenorfin-cam2038-for-behandling-av-opiatberoende/2016-11-14https://www.camurus.com/sv/media/pressmeddelanden/2016/camurus-presenterar-uppdatering-av-bolagets-kliniska-utvecklingsprogram-pa-jefferies-2016-healthcare-conference/2016-11-11https://www.camurus.com/sv/media/pressmeddelanden/2016/delarsrapport-januari-september-2016/2016-11-08https://www.camurus.com/sv/media/pressmeddelanden/2016/camurus-ab-anordnar-kapitalmarknadsdag-14-december-2016/2016-11-01https://www.camurus.com/sv/media/pressmeddelanden/2016/valberedning-utsedd-infor-arsstamma-2017-i-camurus/2016-10-28https://www.camurus.com/sv/media/pressmeddelanden/2016/camurus-utvidgar-samarbetet-med-braeburn-pharmaceuticals-med-ny-kombinationsprodukt-mot-smarta-och-illamaende/2016-10-24https://www.camurus.com/sv/media/pressmeddelanden/2016/camurus-och-braeburn-pharmaceuticals-presenterar-nya-data-fran-tre-kliniska-studier-av-langtidsverkande-buprenorfin/2016-10-21https://www.camurus.com/sv/media/pressmeddelanden/2016/camurus-och-braeburn-pharmaceuticals-inleder-fas-3-studie-av-cam2038-for-behandling-av-kronisk-ryggsmarta/2016-09-30https://www.camurus.com/sv/media/pressmeddelanden/2016/delarsrapport-januari-juni-2016/2016-07-14https://www.camurus.com/sv/media/pressmeddelanden/2016/camurus-meddelar-slutford-fas-2-studie-av-cam2029-i-patienter-med-akromegali-och-neuroendokrina-tumorer/2016-07-12https://www.camurus.com/sv/media/pressmeddelanden/2016/camurus-meddelar-resultat-fran-fas-2-studie-av-cam2032-i-patienter-med-prostatacancer/2016-06-21https://www.camurus.com/sv/media/pressmeddelanden/2016/richard-jameson-nytilltradd-chief-commercial-officer-pa-camurus/2016-06-20https://www.camurus.com/sv/media/pressmeddelanden/2016/camurus-delarsrapport-januari-mars-2016/2016-05-17https://www.camurus.com/sv/media/pressmeddelanden/2016/camurus-och-braeburn-pharmaceuticals-meddelar-positiva-resultat-fran-en-fas-2-studie-av-cam2038-i-opiatberoende-patienter/2016-05-11https://www.camurus.com/sv/media/pressmeddelanden/2016/beslut-vid-camurus-arsstamma-2016/2016-05-03https://www.camurus.com/sv/media/pressmeddelanden/2016/distributionsavtal-tecknat-med-r-pharm-us-for-episil/2016-04-21https://www.camurus.com/sv/media/pressmeddelanden/2016/camurus-och-braeburn-pharmaceuticals-meddelar-att-rekryteringsmalen-uppfyllts-i-tva-fas-3-studier-av-cam2038-for-behandling-av-opiatberoende/2016-04-05https://www.camurus.com/sv/media/pressmeddelanden/2016/kallelse-till-arsstamma-2016-och-forslag-om-nytt-incitamentsprogram-i-camurus-ab-publ/2016-03-30https://www.camurus.com/sv/media/pressmeddelanden/2016/camurus-arsredovisningen-for-2015-offentliggjord/2016-03-30https://www.camurus.com/sv/media/pressmeddelanden/2016/camurus-och-braeburn-pharmaceuticals-startar-fas-2-studie-i-opiatberoende-patienter-med-kronisk-smarta/2016-02-22https://www.camurus.com/sv/media/pressmeddelanden/2016/bokslutskommunike-januari-december-2015/2016-02-17https://www.camurus.com/sv/media/pressmeddelanden/2016/valberedning-utsedd-infor-arsstamma-2016-i-camurus/2016-02-04https://www.camurus.com/sv/media/pressmeddelanden/2016/camurus-och-rhythm-annonserar-licensavtal-for-langtidsverkande-fluidcrystal-setmelanotide/2016-01-05https://www.camurus.com/sv/media/pressmeddelanden/2015/camurus-och-braeburn-pharmaceuticals-annonserar-forsta-dosering-i-fas-3-effektstudie-av-langtidsverkande-behandling-av-opiatberoende-patienter/2015-12-30https://www.camurus.com/sv/media/pressmeddelanden/2015/andring-av-antalet-aktier-och-roster-i-camurus/2015-12-30https://www.camurus.com/sv/media/pressmeddelanden/2015/camurus-och-braeburn-pharmaceuticals-inleder-fas-3-studie-av-langtidsverkande-behandling-for-opiatberoende/2015-12-15https://www.camurus.com/sv/media/pressmeddelanden/2015/camurus-utser-chief-commercial-officer/2015-12-14https://www.camurus.com/sv/media/pressmeddelanden/2015/utnyttjande-av-overtilldelningsoption-i-borsintroduktionen-av-camurus/2015-12-10https://www.camurus.com/sv/media/pressmeddelanden/2015/slutligt-pris-i-camurus-borsintroduktion-har-faststallts-till-57-sek-per-aktie--handeln-inleds-idag-pa-nasdaq-stockholm/2015-12-03https://www.camurus.com/sv/media/pressmeddelanden/2015/camurus-offentliggor-borsintroduktion-pa-nasdaq-stockholm/2015-11-19https://www.camurus.com/sv/media/pressmeddelanden/2015/fda-har-beviljat-fast-track-status-for-utveckling-av-cam2038-langtidsverkande-subkutant-buprenorfin-for-behandling-av-opiatberoende/2015-11-04https://www.camurus.com/sv/media/pressmeddelanden/2015/camurus-ab-delarsrapport-januari---september-2015/2015-10-22https://www.camurus.com/sv/media/pressmeddelanden/2015/solasia-och-camurus-ingar-ett-exklusivt-licensavtal-avseende-forsaljning-och-distribution-av-episil-munhalevatska-i-japan-och-kina/2015-03-30https://www.camurus.com/sv/media/pressmeddelanden/2014/camurus-och-braeburn-pharmaceuticals-ingar-exklusivt-licensavtal-for-langtidsverkande-subkutant-buprenorfin-for-behandling-av-opiatberoende-och-smarta/2014-11-20https://www.camurus.com/sv/media/mediakontakt/2025-02-13https://www.camurus.com/sv/media/mediearkiv/2021-11-02https://www.camurus.com/sv/karriar/2026-03-13https://www.camurus.com/sv/karriar/daniel-mate/2022-04-27https://www.camurus.com/sv/karriar/lina-akesson/2022-04-27https://www.camurus.com/sv/karriar/carola-seibold/2022-04-27https://www.camurus.com/sv/karriar/daniel-corbee/2022-04-27https://www.camurus.com/sv/kontakt/2025-07-15https://www.camurus.com/sv/us/2024-11-13